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Abstract
Nutrigenomics in human peripheral blood mononuclear cells. The effects 
of fatty acids on gene expression profiles of human circulating cells as 
assessed in human intervention studies
PhD thesis by Mark Bouwens, Division of Human Nutrition, Wageningen 
University, Wageningen, the Netherlands, February 20, 2009
Peripheral blood mononuclear cells (PBMCs) are circulating immune cells. Gene 
expression profiles of PBMCs have been increasingly used as diagnostic biomar-
kers for diseases such as leukemia and multiple sclerosis. PBMCs are relatively 
easy and less invasively to obtain compared with other human tissues. Although 
nutrition has been shown to play a pivotal role in the development of diseases 
such as diabetes mellitus type 2 and the metabolic syndrome, up until now lit-
tle was known about the effects of nutrition on PBMC gene expression profiles. 
Nutrients such as polyunsaturated fatty acids (PUFAs) have been shown to have a 
profound impact on metabolism, through activation of transcription factors such 
as peroxisome proliferator-activated receptors (PPARs), resulting in numerous 
changes in gene transcription. This has been mainly demonstrated in various in 
vitro cell and in vivo animal models. Since PBMCs express PPARs, they may be 
very suitable to study the effect of fatty acids on gene expression profiles in vivo 
in the human situation.
In this thesis we examined the effects of several fatty acids on the gene expres-
sion profiles of human PBMCs, using whole genome microarray analysis in ex vivo 
incubation experiments and human intervention studies. We demonstrated that 
fasting, which elevates levels of endogenous free fatty acids in the blood, results 
in changes in gene expression profiles of PBMCs. These changes in gene expres-
sion partially seemed to be mediated through PPARα activation. The function of 
PPARα in human PBMCs was further explored by means of microarray analysis. 
We concluded that PBMCs are suitable cells to study the effects of PPAR-medi-
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ated processes in healthy humans. In addition, we showed that fatty acids affect 
PBMC gene expression profiles in healthy humans during a postprandial inter-
vention as well as after a long-term dietary intervention. This resulted in distinct 
fatty acid specific gene expression profiles, and revealed that long term effects of 
dietary fatty acids are different from postprandial effects. Moreover, we demon-
strated that the application of whole genome PBMC gene expression profiles is a 
very sensitive method, as we were able to detect effects that were previously only 
observed in in vitro and animal experiments. In summary, we conclude that gene 
expression profiles of human PBMCs can be used to reflect changes in dietary 
fatty acid intake. These results provide an encouraging basis for future research 
in which the utility of PBMC gene expression profiles as preventive diagnostic 
tools for nutrition-related disorders can be investigated. 
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Chapter 1
General introduction
Nutrigenomics
Nutrigenomics is the study of the genome-wide impact of nutrition to understand 
the subtle associations between nutrition and health1. This can be examined on 
several levels, including the genome, the transcriptome, the proteome and the 
metabolome. Genomics is the study of an organisms entire genome, transcrip-
tomics is the analysis of the expression levels of all mRNAs in a cell population 
or an organ, proteomics is the large-scale study of proteins, their structures and 
interactions and metabolomics examines and profiles the collection of all me-
tabolites in a biological organism. Although a significant number of studies on 
the genome-wide impact of nutrition and bioactive food components have been 
performed in vitro and in animal models2, 3, nutrigenomics studies on healthy hu-
man subjects are still limited in number.
Transcriptomics
Transcriptomics utilizes high-throughput genomic tools, such as DNA microar-
rays, to examine expression of thousands of genes, at a given time and under vari-
ous conditions including environmental (e.g. nutritional) challenges. In this way, 
patterns of gene expression can be used to get insights in genome-wide effects 
of a particular stimulus and on the potential involvement of specific regulatory 
pathways involved in the transcriptional regulation. The use of high-throughput 
genomic tools has already proven to be extremely valuable in molecular medi-
cine and pathology, where it improved the understanding of the pathogenesis of 
complex diseases4 and brought new diagnostic opportunities5, 6. Transcriptomics 
in humans has not only shown to be able to distinguish a pathological state from 
the normal, non-pathological state, but is also able to provide detailed patterns 
that reflect different stages in disease progression7-9. These features show the 
potential of gene expression profiles to be predictive for metabolic changes and 
the usefulness of these profiles as diagnostic tools10.
Tissue availability 
The major disadvantage in transcriptomics studies in healthy humans is the 
availability of tissue because of the invasiveness of biopsy procedures. Most of 
the reported human transcriptomics studies have been performed with patients 
that had to undergo tissue sampling for medical and/or diagnostic purposes. In 
healthy humans the main options for tissue sampling procedures for nutrige-
10 | Chapter 1
General introduction | 11
nomics studies are muscle and adipose tissue biopsies. However, these are still 
quite cumbersome and painful procedures. In contrast with muscle and adipose 
tissue biopsies, blood is a relatively easily obtainable tissue in healthy subjects. 
However, RNA extraction from whole blood has the disadvantage of a large back-
ground of globin RNA, originating from immature erythrocytes. Besides erythro-
cytes, blood contains thrombocytes, small cytoplasmic bodies derived from cells, 
and leukocytes. In nearly all mammals the nucleus of erythrocytes has been 
extruded during the final maturation stage, making them unsuitable for gene ex-
pression analysis. Thrombocytes contain only limited amount of RNA and are 
thus difficult to employ. Leukocytes do not have these limitations and can be 
found throughout the body, including the peripheral blood and lymphatic sys-
tem. These cells can be divided in two varieties, mononuclear and polynuclear 
cells. The peripheral blood mononuclear cells (PBMCs) include the lymphocytes 
and the monocytes.
Peripheral blood mononuclear cells
PBMCs are relatively easy to isolate from whole blood. Gene expression profiles of 
PBMCs have been used to distinguish a variety of diseases from the health state, 
to differentiate between disease stages, and to predict clinical outcome 7-9, 11-16. 
Another study identified genes that are differentially expressed in the different 
cells within PBMCs17. Also, variation in gene expression profiles between and 
within individuals was examined in various studies17-19, which demonstrated that 
variation in PBMC gene expression profiles is relatively high between subjects, 
but far lower within individuals over time. 
PBMCs are a critical component in the immune system to fight infection and 
adapt to invading microorganisms. Lymphocytes are the largest subpopulation 
within PBMCs and play an important role in the adaptive immune response, 
whereas monocytes are important cells of the innate immune response. The 
adaptive immune system recognizes and remembers specific pathogens, which 
results in stronger attacks each time the pathogen is encountered20. The innate 
immune system provides immediate defense against infections and functions in 
a non-specific manner.
Lymphocytes 
Lymphocytes can be divided into two major groups, the T lymphocytes, which 
develop in the thymus, and B lymphocytes, which originate from the bone mar-
row. T lymphocytes are the largest group, and they are involved in cell mediated 
immunity. B lymphocytes are primarily responsible for the humoral immunity, by 
producing large quantities of antibodies which neutralize foreign invaders such 
as bacteria and viruses. T lymphocytes in turn can be split up in helper T (Th) 
cells, also known as CD4+ lymphocytes, and cytotoxic T (Tc) cells, also known as 
CD8+ lymphocytes. Th cells produce cytokines, that direct the immune response, 
whereas Tc cells produces toxic granules that induce the death of pathogen- 
infected cells20. 
Monocytes 
Monocytes play a large role in the innate immune defense21. In response to in-
flammatory signals, monocytes can move rapidly (approx. 8-12 hours) to sites 
of infection in the tissues and differentiate into macrophages. Macrophages 
perform phagocytosis to remove foreign substances in the body, by binding to 
the microbe directly via pattern-recognition receptors or by using intermediary 
proteins such as antibodies that coat the pathogen. Monocytes are also capable 
of killing infected host cells via antibodies, similar to Tc cells, termed antibody-
mediated cellular cytotoxicity. Macrophages are responsible for protecting tis-
sues from foreign substances, but are also suspected to be the predominant cells 
involved in the development of atherosclerosis. During atherosclerotic develop-
ment, macrophages can take up lipids and differentiate in foam cells, which are 
known as prototypical atherosclerotic cells22. 
Effects of nutrients on gene expression
Nutrients can influence the transcriptional control of gene expression by means 
of specific transcription factors. A very important group within the nutrient sens-
ing transcription factors are the large subfamily of nuclear receptors, with 48 
members. By activation of specific members of this subfamily, nutrients are able 
to influence a wide variety of cellular functions. An example for this principle 
are peroxisome proliferator-activated receptors (PPARs), which serve as most 
important fatty acid sensors in the cells1.
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PPARs
PPARs are ligand-activated transcription factors that bind mainly unsaturated or 
very long-chain fatty acids and their derivatives, which results in transcriptional 
activation. Regulation by PPARs requires heterodimerization with the retinoid X 
receptor (RXR), another nuclear receptor. After activation by ligand binding, the 
PPAR/RXR heterodimer results in transcription via binding to DNA response ele-
ments (PPREs) often present in or near the promoter of target genes (Figure 1). 
This usually results in up-regulation of these genes, but can also result in a 
repression of transcription by interaction with other transcription factors and 
repression of their mechanism of action, a process called transrepression23.
Figure 1 PPAR signaling Ligands, such as unsaturated fatty acids, enter the cell and bind peroxi-
some proliforator-activated receptors (PPARs). 9-cis retinoic acid binds its heterodimeric partner, the 
retinoid X receptor (RXR). The PPAR/RXR heterodimer binds to specific response elements (PPREs) 
located within or near the promoter of PPAR target genes. Binding results in increased expression of 
these target genes, consequently leading to protein synthesis.
Three types of PPARs have been identified: alpha, delta (beta), and gamma24. 
PPARα is mainly expressed in liver, intestine, kidney, heart, skeletal muscle and 
adipose tissue. PPARβ/δ is ubiquitously expressed, but markedly present in 
brain, adipose tissue and skin. PPARγ is expressed in three forms, through alter-
native splicing. PPARγ1 is ubiquitously expressed, PPARγ2 is mainly expressed 
in adipose tissue and PPARγ3 is expressed in macrophages, colon and white adi-
pose tissue. Each of the PPAR subtypes has specific functions, but all three PPARs 
affect energy homeostasis and inflammatory responses24. 
The activity of PPARs can be modulated by drugs such as the hypolipidemic fi-
brates (PPARα) and the insulin sensitizing thiazolidinediones (PPARγ), but fatty 
acids are the natural ligands of these transcription factors. Of all the natural lig-
ands of PPARs, polyunsaturated fatty acids have been shown to activate PPARs 
most profoundly25, 26. 
Fatty acids
As fatty acids are known to alter gene expression, they are suitable candidate nu-
trients to study the effects of nutrition on whole genome gene expression. Fatty 
acids can be grouped by their degree of saturation and length. The main fatty 
acids in the diet are monounsaturated (MUFA) and saturated fatty acids (SFA). 
Polyunsaturated fatty acids (PUFAs) are present in the diet in much lower quan-
tities. However, this low intake of PUFAs is relatively important, since the human 
body can produce most fatty acids it needs, except for two long chain PUFAs. 
These two, linoleic acid (LA) and alpha-linolenic acid (ALA), are found in plant 
oils. In addition, the longer-chain n-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), can only be converted from LA and LNA to some 
extent. It is therefore advised to consume fat fish on a regular basis, since EPA 
and DHA are abundantly present in fish oil. 
Intake of PUFAs has been suggested to have a variety of beneficial health effects, 
ranging from prevention of cardiovascular disease27 and a reduced production of 
inflammatory agents28 to decreased cognitive decline29. It is still unknown how 
the beneficial effects of PUFAs on health are mediated. It is, however, well known 
that these fatty acids are transported though the human body by the blood either 
largely albumin-bound as free unesterified fatty acids (FFA) or as triglyceride in 
the lipoprotein fraction. Fatty acids in blood can originate from two sources, ei-
ther endogenous, from the fatty acid pool stored in adipose tissue, or exogenous, 
directly from the diet. 
During fasting, fatty acids will be released from adipocytes into the bloodstream 
in the form of FFAs. These endogenous FFAs rise during fasting, and drop after a 
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regular meal (postprandial). However, after a high fat meal the concentrations of 
FFA can rise, and the intake of specific fatty acids is reflected in the FFA profile 
in the blood30. 
Postprandial, short- and medium chain fatty acids can be absorbed directly into 
the blood, but long chain fatty acids are to large to be directly absorbed and are 
therefore transported as triglycerides in large lipoprotein particles called chy-
lomicrons, via the lymphatic vessels into the bloodstream. In the blood chylomi-
crons transport these lipids to peripheral tissues such as adipose, cardiac and 
skeletal muscle tissue, where their triglyceride components are broken down by 
the activity of lipoprotein lipase. During a high fat meal an overload of fatty acids 
enter the system and not all fatty acids that are released from chylomicrons are 
absorbed in the peripheral tissue, resulting in a rise in blood FFA, postprandially. 
Besides their elevation during fasting and after a high fat meal, FFA concentra-
tions can also be increased in healthy subjects during long-endurance exercise or 
in less healthy people with obesity and diabetes mellitus type 2, because of the 
reduced capacity of peripheral tissues to rapidly remove FFAs.
Nutritional effects on PBMC gene expression profiles 
In nutrition-related research we are mainly interested in the prevention of dis-
ease, because once the disease is manifested, drug treatment is required and nu-
tritional intervention is of less importance. For that reason nutritional research 
is performed in relatively healthy people. Nutrients like fatty acids are known 
for their effects on health, which can be positive, in the case of PUFAs, or less 
positive, in the case of SFA. How these fatty acids exert their effects on health in 
mainly unknown, but it is known that fatty acids can influence gene expression 
by transcription factors such as PPARs. With the use of genomic tools such as 
transcriptional profiling with DNA microarrays, we can measure all transcrip-
tional regulated processes influenced by fatty acids. In healthy individuals, PB-
MCs are highly suitable to be used for this purpose, since these cells are easily 
obtainable, there gene expression profiles have been used to reflect pathological 
conditions and it has been shown that these cells express the fatty acid sensing 
transcription factor PPARα31, 32. 
Characterization of nutrient-specific effects on gene expression in humans could 
advance understanding of the mechanisms involved in nutritional effects on im-
portant phenotype features such as cellular metabolism and homeostatic control. 
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In the end this could lead to evidence-based dietary advice in order to prevent 
disease-related cellular dysfunction or intervene in a very early state of patho-
logical disarrangements.
Outline of this thesis 
We hypothesized that gene expression profiles of peripheral blood mononuclear 
cells are able to reflect nutritional changes. More specifically, we speculated that 
PBMC gene expression profiles could show the acute and long-term effects of 
both endogenous and dietary fatty acids in healthy humans. To test this hypoth-
esis we initially performed a study in which the endogenous fatty acids in plasma 
of healthy young men were increased by fasting for 48 hours, and changes in 
gene expression profiles of the PBMCs were assessed by whole genome micro-
array analysis (Chapter 2). To further elucidate the role of PPARα in PBMCs an 
ex vivo incubation study using comprehensive whole genome gene expression 
analysis was performed. The fatty acid receptor PPARα was activated by incuba-
tion of the cells with the synthetic PPARα ligand WY14,643 to show the specific 
PBMC PPARα response (Chapter 3). Subsequent studies were performed to re-
veal dietary effects of fatty acids on PBMC gene expression profiles, in a long-
term, double-blind, randomized controlled trial in which healthy elderly sub-
jects were supplemented with the fish fatty acids EPA and DHA or a placebo for 
26 weeks (Chapter 4) and in a single-blind, cross-over postprandial challenge 
study, in which healthy young men consumed shakes containing different fatty 
acids (Chapter 5). In chapter 6 the results described in the previous chapters 
are discussed and evaluated.
1 | Chapter 1
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Abstract
Background
Peripheral blood mononuclear cells (PBMC) are the only readily available cells in 
healthy humans. Various studies showed disease-characteristic gene expression 
patterns in PBMC. However, little is known of nutritional effects on PBMC gene 
expression patterns. Fatty acids (FAs) are nutrients that regulate gene expres-
sion by e.g. activating the nuclear receptor peroxisome proliferators-activated 
receptor alpha (PPARα). PBMC express PPARα, making these cells interesting to 
study FA-dependent gene expression. 
Objective
The aim of this study is to elucidate whether PBMC gene expression profiles also 
reflect nutrition-related metabolic changes. Furthermore, we focused on the spe-
cific role of PPARα in regulation of PBMC gene expression during fasting, when 
plasma free FAs are elevated.
Design
Four healthy male volunteers fasted for 48 hours. PBMC RNA was hybridized on 
Affymetrix whole genome microarrays. To elucidate the role of PPARα, PBMC of 
9 donors were incubated with the specific PPARα ligand Wy14,643.
Results
After 24 and 48 hours fasting, 1,200 and 1,386 genes were changed more than 
1.4 fold, respectively. Many of these genes were involved in FA β-oxidation and 
are known PPARα target genes. Incubation of PBMC with Wy14,643 resulted in 
up-regulation of genes that were also up-regulated during fasting. 
Conclusions
We conclude that PBMC gene expression profiles reflect nutrition-related meta-
bolic changes such as fasting, and that part of the fasting-induced changes are 
likely regulated by PPARα.
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Introduction
White blood cells travel through the entire body and respond to various internal 
and external signals. A subset of white blood cells known as peripheral blood 
mononuclear cells (PBMC) receives increased interest for diagnostic purposes 
since the development of sophisticated transcriptomics techniques such as whole 
genome microarray analysis. The advantage of PBMC above other cells is that 
blood is the most readily accessible cellular material in humans and PBMC can 
be isolated from whole blood relatively easily. Various studies have shown that 
PBMC can display gene expression patterns characteristic for certain diseases, 
such as acute myeloid leukemia, atherosclerosis and auto-immune diseases7-9, 15, 33. 
From physiological studies we know that nutritional effects on parameters of hu-
man physiology are generally smaller than pathophysiological changes. Similarly, 
nutritional-induced changes in PBMC gene expression are expected to be smaller 
than the described effects observed in various diseases. Characterization of nutri-
ent-specific effects on cellular metabolism and homeostatic control could in the 
end lead to evidence-based dietary advice in order to prevent disease or inter-
vene in a very early pre-disease state. The comprehensive understanding of the 
mechanisms involved in nutritional effects on gene expression is of considerable 
importance in this respect. This is especially the case in PBMC, since obtaining 
alternative cellular material, through invasive tissue biopsies, is not always feasi-
ble or even possible in healthy volunteers, because of ethical reasons. Therefore, 
the ability to detect diet-induced changes in gene expression profiles of relatively 
easily obtainable PBMC could not only be highly valuable for the identification of 
nutrient-related molecular mechanism, but will also be of pivot importance to 
study the development of diet-related chronic disorders. It is known that several 
nutrients are able to activate gene expression by binding to transcription fac-
tors1. This is quite well understood for fatty acids (FA)34, which mediate their 
modulatory effects on changes of expression levels of specific genes by a group 
of nuclear receptors, the peroxisome proliferators-activated receptors (PPAR). 
These ligand-activated transcription factors (PPARα, PPARβ/δ, PPARγ) bind FA, 
in particular if they are unsaturated, which results in transcriptional activation. 
Activation of PPARα occurs e.g. when plasma free fatty acid (FFA) concentrations 
are increased in situations such as fasting and heavy exercise, postprandially and 
in conditions such as diabetes type II and visceral obesity. Fasting results in the 
most pronounced elevation in plasma FFA, due to breakdown of triacylglycer-
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ols stored in the adipose tissue35. Studies in liver from fasted mice showed that 
PPARα transcriptionally activates genes involved in processes essential for uti-
lization of increased FA concentrations for energy, such as β-oxidation36. Since 
previous studies showed that PPARα is expressed in human PBMC31, 32, 37, and 
FA are abundantly present in blood plasma of fasting humans, these nutrients 
are excellent candidates to study the feasibility of detecting and analyzing nutri-
ents-induced changes in PBMC gene expression profiles. In order to assess this, 
we conducted a study in which four healthy men fasted for 48 hours, monitored 
changes in PBMC gene expression during fasting by whole genome microarray 
analysis, and examined the role of PPARα in this respect.
 
Subjects, Materials and Methods
Recruitment of subjects
Four healthy male Caucasian volunteers, between 19 and 22 years of age were 
recruited from the Wageningen student population. Physiologically measured 
exclusion criteria were a body mass index (BMI) < 19 or > 25 kg/m2, urine pro-
tein or glucose concentrations outside normal ranges or fasting blood glucose 
outside the normal range. Other exclusion criteria were: tobacco smoking, taking 
regular prescribed medication, received inoculations within 2 months of starting 
the study or planned to during the study, donated or intended to donate blood 
within 8 weeks of the first and last study samples, diagnosed with any long-term 
medical condition (eg., diabetes, hemophilia, cardiovascular disease, anemia, 
gastrointestinal disease), experiencing symptoms of allergy or vegetarian. Sub-
jects were informed about the design and purpose of the study and provided full 
informed written consent.
Study design of the intervention study
At a screening visit, urine and fasting venous blood samples were taken to deter-
mine glucose concentrations in both urine and blood, and protein concentrations 
in urine. Four healthy male subjects who fulfilled selection criteria were included 
in the study. Volunteers received an identical meal at 5 pm, before the start of a 
48 hour fasting period. During the fasting period, the subjects were not allowed 
to eat or drink anything except water, which they could consume ad libitum. Af-
ter 48 hours, the volunteers received a light meal. After 0, 24 and 48 hours of 
fasting, 45 ml of blood was drawn into EDTA tubes from the antecubital vein in 
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each volunteer’s forearm. Volunteers were asked to keep record of their physical 
condition and after 15 hours of fasting they remained under constant supervi-
sion. The total study was repeated two months later with the same subjects. The 
study protocol was approved by the Medical Ethical Committee of Wageningen 
University.
Blood glucose and plasma free fatty acids
Blood glucose concentrations were determined with Accu-Chek Compact blood 
glucose meters (Roche Applied Science). Immediately after blood drawing, blood 
was centrifuged and plasma was stored at -80˚ C. Plasma free fatty acids were 
measured by gas–liquid chromatography (GLC)38, 39. Briefly, plasma was incu-
bated with a modified Dole reagent (2-propanol/heptane/2 M orthophosphoric 
acid, 40:10:1) for 10 min a room temperature. Heptane was added and the tubes 
were mixed (5 minutes) and centrifuged at 3000 rpm for 5 minutes. The upper 
heptane layer was transferred to another tube and evaporated under nitrogen. 
The residue was solved in chloroform and FFA were separated from the triacylg-
lycerols and phospholipids on amino propyl columns. The FFA were hydrolyzed 
in 0.5 N methanolic sodium-hydroxide and methylated with borontrifluoride 
in methanol. The methyl esters were separated on a glass capillary column and 
measured with a flame ionization detector. Identification of individual methyl 
esters was performed by comparisons with authentic standard mixtures. Hep-
tadecanoic acid (C17:0) was used as an internal standard for quantification of 
individual free fatty acids.
PBMC isolation for the intervention study
Immediately after blood collection, PBMC were isolated out of 36 ml blood, from 
all time points and subjects for both study periods, using Optiprep (Axis-shield, 
Oslo, Norway) according to the manufacturer’s manual. 
PBMC isolation for cell culture
Buffy coats from 9 blood donors were acquired through the blood bank (Sanquin, 
Nijmegen, the Netherlands). Blood donors were healthy Caucasian men, aged 
between 18 and 40 yr, which gave informed consent. PBMC were isolated directly 
after arrival of the buffy coat (at most 8 hours after donation) by Ficol-paque Plus 
density gradient centrifugation (Amersham Biosciences, Roosendaal, the Nether-
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lands). Cells were washed twice in RPMI1640 medium and isolated cells were 
counted and tested for viability by trypan blue exclusion prior to culture.
PBMC cell culture
PBMC were cultured using RPMI1640 medium with 2 mmol/L L-glutamine, 10% 
fetal bovine serum and antibiotics (penicillin and streptomycin) in the presence 
of 5% CO2 at 37°C. Cell culture medium containing glutamine and serum were 
purchased from Gibco BRL (Grand Island, NY). PBMC were incubated at 1.0 x 106 
cells per ml with 50 μmol/L Wy14,643, or 0.1% DMSO (vehicle), for 12 hours. Fol-
lowing incubation, the cells were collected, washed twice in phosphate-buffered 
saline, and counted and tested for viability by trypan blue exclusion. 
Flow cytrometric analysis of PBMC vitality
Viability of the cells after incubation with 50 μmol/L Wy14,643 was determined 
by staining with annexin/ propidium iodide (PI) followed by flow cytometry 
analysis with a Coulter Epics XL.MCL flow cytometer (Beckman Coulter).
Total RNA isolation
PBMC RNA was isolated from all PBMC samples using Qiagen RNeasy Micro kit 
(Qiagen, Venlo, the Netherlands). RNA yield was quantified on a Nanodrop ND 
1000 spectrophotometer (Nanodrop technologies, Wilmington, Delaware USA) 
and integrity was measured on an Agilent 2100 Bioanalyzer with RNA 6000 
Nano chips (Agilent Technologies, South Queensferry, UK). 
Microarray processing
From the twelve PBMC RNA samples from the first study, eleven samples were 
used for microarray processing. One sample from the first study was excluded 
due to low RNA quality. One microgram of total RNA per sample was labelled 
using a one-cycle cDNA labelling kit (Affymetrix Inc, Santa Clara, CA) and 
hybridized to Affymetrix Human whole genome U133 plus 2.0 arrays (Affyme-
trix). Sample labeling, hybridization to chips and image scanning was performed 
according to the manufacturer’s GeneChip Expression Analysis Technical Manual 
(Affymetrix).
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Microarray data analysis
Quality control was performed and fulfilled the criteria for array hybridization 
suggested by the Tumor Analysis Best Practices Working Group40. Expression 
values were calculated using the Robust Multichip Average (RMA) method. RMA 
signal value estimates are based on a robust average of background corrected 
perfect match intensities and normalization was done using quantile normaliza-
tion41, 42. Probe sets were filtered using the Inter Quartile Range (IQR)43, using a 
cut off value of 0.3. Only probe sets with normalized signals higher then 20 on 
at least two arrays were defined as expressed and selected for further analysis. 
Individual probe sets were defined as ‘changed’ when comparison of the normal-
ized signal intensities showed a p-value lower then 0.05 in a two-tailed paired t 
test. For pathway analysis, only probe sets with an average fold change of >1.4 
or <-1.4 between 0 and 24 hours, or 0 and 48 hours were selected. Conversion 
of number of probe sets to amount of genes was performed by using the DAVID 
Gene ID conversion tool (DAVID Bioinformatic Resources 2006, http://niaid.
abcc.ncifcrf.gov/conversion.jsp). Pathway analysis was performed using Gen-
MAPP 2.044 (http://www.genmapp.org/). The MAPPFinder software was used 
to rank the GenMAPP local pathways by z-score during fasting. Z-scores in this 
software program are calculated by subtracting the expected number of genes 
meeting the criterion from the observed number, divided by the standard devia-
tion of the observed number of genes.
cDNA synthesis and Quantitative Real Time PCR
RNA was reverse transcribed using the iScript cDNA synthesis kit (Biorad). Stand-
ard quantitative real time polymerase chain reaction (Q-PCR) was performed us-
ing Platinum Taq DNA polymerase and SYBR Green on an iCycler PCR machine 
(Bio-Rad Laboratories BV, Veenendaal, The Netherlands) and duplicated at least 
twice. Primer sequences used in the PCRs were chosen based on the sequences 
available in PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html). 
Q-PCR data were normalized by measuring cycle threshold (Ct) ratios between 
candidate genes and a housekeeping gene, human acidic ribosomal phosphopro-
tein PO (HuPO), which was shown to be consistent within PBMC45. 
Statistical methods
A two-tailed paired t test was used to determine significant differences in plasma 
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metabolite concentrations and Q-PCR gene expression values between baseline 
and 24 hours of fasting, and between baseline and 48 hours of fasting. We applied 
Bonferroni corrections as an adjustment for multiple testing and defined statisti-
cal significance at p<0.025. For the ex vivo experiments statistical significance 
was accepted at p<0.05. All calculations were performed by using the SPSS-soft-
ware package 12.0.1 (Chicago, Illinois).
 
Results
Volunteer characteristics
All four volunteers completed both 48 hour fasting periods without any prob-
lems. The characteristics of the subject population are presented in Table 1, in 
which the glucose concentrations are measured during the screening after an 
overnight fast. Fasting during the study resulted in a decrease in glucose con-
centrations, from an average of 4.2 mmol/L directly after the meal, to an aver-
age of 3.6 mmol/L after 48 hours (data not shown). Changes in individual free 
fatty acids are shown in Figure 1. All plasma free fatty acid concentrations were 
strongly elevated after 24 hours fasting and remained elevated after 48 hours 
fasting. The mean increases after 48 hours fasting in mono-unsaturated fatty ac-
ids (MUFA), saturated fatty acids (SFA) and poly-unsaturated fatty acids (PUFA) 
were 10, seven and six times the basal concentration, respectively (Figure 1A). 
Within the PUFA the n-3 and n-6 fatty acids increased four and six times within 
48 hours fasting (Figure 1B).
Table 1 Subject characteristics of the men participating in the study.
Mean (n=4) Range
Age (y) 20.6 19 – 22
Height (m) 1.84 1.80 – 1.87
Weight (kg) 72 68 – 79
BMI (kg/m2) 21.3 20.4 – 22.6
Fasting glucose (mmol/L) * 5.2 4.9 – 5.7
* Glucose values were determined after an overnight fast during the screening visit
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Figure 1 Mean plasma free fatty acid concentrations during fasting. A. SFA, Saturated fatty acids; 
MUFA, mono-unsaturated fatty acids; PUFA, poly-unsaturated fatty acid. B. n-3 FA, omega-3 fatty 
acids; n-6 FA, omega-6 fatty acids. Asterisks indicates significant change compared to t=0 (* p <0.025; 
** p <0.01) as determined with a paired t-test. Bars represent mean ± SD (n=4).
Differential gene expression on microarray
Fasting for 24 and 48 hours resulted in a differential expression of 3,582 out of a 
total of 54,675 tested probe sets in PBMC (Figure 2). These changed probe sets 
encoded for 3,030 genes. After selection of probe sets with a signal higher then 
20 in at least 2 arrays and a fold change higher than 1.4 or lower than -1.4, 1,200 
genes were changed after 24 hours and 1,386 genes after 48 hours. Most of these 
genes showed an up-regulation in expression, i.e. 74% after 24 hours and 78% 
after 48 hours. Of the genes meeting the selection criteria more than 74% were 
changed at both time points.
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Figure 2 Stepwise probe set selection in microarray analysis. 
Pathway analysis
Subsequent pathway analysis of the microarray data revealed that several genes 
that exhibited increased expression upon fasting were involved in fatty acid 
metabolism and, more specifically, in fatty acid β-oxidation (Figure 3). Further-
more, pyruvate metabolism and most of the RNA/DNA metabolism pathways 
were up-regulated upon fasting in PBMC. A decreased expression of genes in-
volve in the TCA cycle was observed. Most pathways were already changed after 
24 hours, which sustained until 48 hours. Exceptions were regulation of viral 
genome replication and B-cell differentiation, which only showed up-regulation 
after 48 hours and heme biosynthesis, which only showed down-regulated at 48 
hour. Another exception was negative regulation of transcription, which showed 
up-regulated and down-regulation of genes in the same “pathway”, leading to 
both an increase and decrease at 24 hours.
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24h 48h
MAPPName up down up down
Fatty acid metabolism
carnitine O-palmitoyltransferase activity
O-palmitoyltransferase activity
palmitoyltransferase activity
3-oxoacyl-[acyl-carrier protein] reductase activity
fatty-acid synthase activity
carnitine O-acyltransferase activity
fatty acid beta-oxidation
fatty acid oxidation
acetyl-CoA C-acyltransferase activity
Pyruvate metabolism
lipoate biosynthesis
pyruvate transporter activity
RNA/DNA metabolism
heterogeneous nuclear ribonucleoprotein complex
regulation of viral genome replication
RNA processing
B-cell differentiation
negative regulation of transcription
small ribosomal subunit
cytoplasmic microtubule
Other
glyoxylate metabolism
heme biosynthesis
histone-lysine N-methyltransferase activity
procollagen N-endopeptidase activity
TCA cycle
alpha-ketoglutarate dehydrogenase complex
TCA cycle enzyme complex (sensu Eukarya)
Figure 3 Heat map of changed pathways after 24 hours and 48 hours of fasting in peripheral blood 
mononuclear cells ranked by Z-scores (GeneMAPP 2.0). Only pathways with z-scores higher than 1 
at either 24 or 48 hours were included. Z-scores for down-regulated pathways were inverted. Red 
indicates up-regulated, green indicates down-regulated. 
Specific gene expression 
Of all the genes changed after 24 and 48 hours of fasting (additional file), 
pyruvate dehydrogenase kinase, isoform 4 (PDK4) showed the largest changes 
in gene expression with increases of 7.2 and 7.4 after 24 and 48 hours fasting, 
respectively. This gene is known to be regulated by PPARα. Table 2 shows a list 
of the genes which expression we found to be changed after fasting and that are 
known PPARα target genes from mice studies. Interestingly, expression of all 
these PPARα target genes was up-regulated, either at 24 hour, 48 hours or at 
both time points. Many of these genes are involved in fatty acid β-oxidation, such 
as carnitine palmitoyltransferase 1 (CPT1), acetyl-Coenzyme A acyltransferase 2 
(ACAA2), solute carrier family 25 (carnitine/acylcarnitine translocase), member 
20 (SLC25A20), acyl-Coenzyme A dehydrogenase, very long chain (ACADVL) and 
acyl-Coenzyme A thioesterase 2 (ACOT2).
Table 2 Known PPARα target gene expression in peripheral blood mononuclear cells on the microarrays.
Affy ID Genename Description Mean signal
Mean FC 
24vs01,2
Mean FC 
48vs01,2
225207_at  PDK4 pyruvate dehydrogenase kinase, isoenzyme 4 >50 7.19 7.40
205960_at  PDK4 pyruvate dehydrogenase kinase, isoenzyme 4 >50 7.10 6.81
203633_at  CPT1A carnitine palmitoyltransferase 1A (liver) >50 2.05 2.08
210688_s_at  CPT1A carnitine palmitoyltransferase 1A (liver) 20-50 1.75 1.94
210069_at  CPT1B carnitine palmitoyltransferase 1B (muscle) >50 1.79 1.73
210070_s_at  CPT1B carnitine palmitoyltransferase 1B (muscle) 20-50 NC 1.40
203658_at  SLC25A20 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 >50 1.93 1.87
209122_at  ADFP adipose differentiation-related protein >50 1.93 1.85
202003_s_at  ACAA2 acetyl-Coenzyme A acyltransferase 2 >50 1.61 1.61
200710_at  ACADVL acyl-Coenzyme A dehydrogenase, very long chain >50 1.47 1.46
213524_s_at  G0S2 G0/G1switch 2 >50 4.80 NC
202982_s_at  ACOT2 acyl-CoA thioesterase 2 20-50 NC 1.53
1 All fold changes (FC) are significant (p<0.05).
2 All genes were up-regulated. NC indicates not changed significantly.
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Confirmation of gene expression data
To confirm the data found with microarray analysis and to observe whether the 
changes were consistent, quantitative real time PCR (Q-PCR) was performed on 
RNA from the first and the second study (Figure 4). Genes chosen for confirmation 
were PDK4 and several genes involved in fatty acid β-oxidation. For all genes the 
mode of change observed with microarray analysis could be confirmed by Q-PCR, 
although changes were smaller. Q-PCR changes after 48 hours of fasting, but not 
after 24 hours, were significant for PDK4 and SLC25a20. In the second study, all 
genes were significantly changed at 48 hours, except for CPT1, which showed 
no significant change. Changes at 24 hours in the second study were increased 
significantly for PDK4 and SLC25A20 (Figure 4).
Figure 4 Microarray and real-time gene expression changes of four PPARα target genes after 24 and 
48 hours fasting in both intervention studies. Dots represent fold changes of the individual subjects 
and lines represent mean values. P-values were determined with a paired t-test. Asterisk indicates 
significant change compared to t=0 (p <0.025). 
Cell culture experiments 
Several of the genes changed upon fasting are known PPARα target genes. To reveal 
whether those genes can be activated via PPARα in PBMC, freshly isolated PBMC 
from 9 healthy male donors were used in cell culture experiments. Incubation 
of these PBMC with 50 μmol/L of the highly specific PPARα ligand Wy14,643 
revealed an increase in expression of PDK4, CPT1, ACAA2 and SLC25A20, 
compared to the control cells, which were incubated with vehicle (Figure 5). 
PPARα expression itself was not changed upon incubation with Wy14,643. PBMC 
showed no loss of viability after incubation with 50 μmol/L of Wy14,643 for 12 
hours (data not shown).
Figure 5 Changes in gene expression of four PPARα target genes and PPARα in PBMC of nine donors 
after incubation with 50μmol/L of Wy14,643 for 12 hours. Dots represent different donors, lines 
represent mean values. * significantly changed compared to vehicle (p <0.01) as determined with a 
paired t-test.
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Discussion
Here we demonstrate that elevated concentrations of plasma free fatty acid 
during fasting have pronounced effect on PBMC gene expression, in particular 
on expression of PPARα target genes. Correspondingly, pathway analysis showed 
a strong increase in genes involved in fatty acid metabolism, and, more specific, 
of the fatty acid β-oxidation in PBMC. The functionality of PPARα in PBMC was 
demonstrated in an ex-vivo study in which we showed that PPARα is responsible 
for an increased transcription of genes involved in fatty acid β-oxidation when 
these cells are incubated with the highly specific PPARα ligand Wy14,643.
So far, mainly disease-related PBMC genomic fingerprints have been revealed 
with transcriptomics techniques7-9, 15, 33. We observed that even during a 
metabolic condition such as fasting, when fatty acids are elevated, microarray 
analyzes can reveal many differentially expressed genes in PBMC. These gene 
expression changes are not only observed after 48 hours, but are already present 
after 24 hours of fasting. The clear overlap in genes changed at both time points 
is also reflected in a similar change in pathways after 24 hours and 48 hours 
of fasting. Interestingly, the number of genes changed in PBMC is quite large, 
especially if the low number of four subjects included in the study is taken into 
account. To assure that the gene expression changes were truly due to fasting, 
the whole study was repeated two months later with the same persons. In this 
second study, we observed that several of the genes, which expression was 
changed in the first study, were also changed, demonstrating the consistency of 
our microarray findings. In addition, the high number of genes changed and the 
consistency of the findings indicate that fasting has a profound effect on gene 
expression in PBMC. These promising results implicate that PBMC may also 
be used to monitor more subtle effects associated with dietary intervention, 
providing that sufficient numbers of subjects are included. 
While a large number of genes were changed after fasting, many of the genes 
changed play a role in metabolic pathways normally regulated during fasting in 
the liver, such as an increase in fatty acid β-oxidation and a decrease in the TCA-
cycle35. During fasting, when free fatty acids are used as the main fuel source, 
fatty acid β-oxidation will be up-regulated to provide acetyl coenzyme A (CoA), 
subsequently used in the TCA-cycle. Our study showed that genes involved in 
fatty acid β-oxidation were also up-regulated in PBMC after fasting. Interestingly, 
as known from mice studies, the expression of several of these genes is regulated 
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by the fatty acid-activated nuclear receptor PPARα. In these mice studies, fasting 
has been shown to activate PPARα in liver, resulting in up-regulation of processes 
such as fatty acid β-oxidation36. Moreover, the gene with the most profound up-
regulation, pyruvate dehydrogenase kinase (PDK)4, is also known to be regulated 
by PPARα during fasting in rat skeleton muscle and heart46, 47. PDK4 executes its 
role during fasting by inhibiting the pyruvate dehydrogenase complex (PDC), 
thereby decreasing conversion of pyruvate to acetyl CoA leading to conservation 
of glucose. PDK4 is expressed at high levels in various tissues, predominantly in 
heart and skeletal muscle, but also liver and kidney48. The role of human PDK4 
during fasting has mainly been studied in skeletal muscle, in which, similar to 
our study, PDK4 expression was increased49-51. The functionality of PPARα, with 
respect to its capability to increase the expression of genes involved in fatty acid 
β-oxidation and PDK4 in PBMC, was proven by the ex vivo incubation with the 
specific PPARα ligand Wy14,643. We showed that these PPARα target genes were 
up-regulated in PBMC from 9 different donors after incubation with the ligand. 
This indicates that PPARα is functional in PBMC and likely mediates the fatty acid 
dependent gene expression in these cells. It has previously been reported that 
PPARα-controlled genes in mice T-cells could only be up-regulated by ligand-
induced activation of PPARα when histone deacetylase inhibitors are utilized52. 
Interestingly, we found an up-regulation of PPARα target genes in freshly isolated 
human PBMC, consisting of roughly 60% T-cells, without addition of histone 
deacetylase inhibitors. In addition, it has also been reported that activation 
of PPARα during fasting or with the PPARα ligand Wy14643 results in an up-
regulation in expression of PPARα itself in liver tissue of mice studies and from in 
vitro studies with human primary hepatocytes36, 53. We however did not observe 
such auto-regulation of PPARα in human PBMC, neither during fasting nor after 
incubation of the cells with Wy14,643. Both studies showed no change in gene 
expression of PPARα. We speculate that this auto-regulation is less pronounced 
in or not present in PBMC, which may explain the discrepancies between the 
studies performed in either mouse or other human tissues.
We found in our study a sizable variation in both basal expression of the genes, as 
in gene expression changes, between the subjects. This not only points towards a 
large variation between persons, but also to a large variety in the gene expression 
response towards a metabolic change. From microarray studies it is reported 
that not only variation in PBMC basal gene expression between human subjects 
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can be very large, but also that there is a sizable variation in proportions of PBMC 
subpopulations between individuals, which might explain the large variation in 
individual response17-19. However, all studies report that within one individual, 
variety is relatively small, both in PBMC gene expression and subpopulations, 
and has little effect on PBMC gene transcription profiles. Therefore, dietary 
intervention studies with multiple measurements within the same individual are 
necessary for the detection of gene expression changes in PBMC. 
Concisely, our study shows that during fasting, blood free fatty acids are elevated, 
activating PPARα in the blood cells i.e. the PBMC, thereby inhibiting the conversion 
of pyruvate to acetyl CoA to conserve glucose, by up-regulating PDK4 and at the 
same time increasing fatty acid β-oxidation to provide energy by metabolizing 
the released free fatty acids. This elevated fatty acid β-oxidation increases the 
lipid handling capacity of PBMC. From all fatty acids, polyunsaturated fatty 
acids have been shown to activate PPARα most profoundly25, 26. We therefore 
hypothesise that these fatty acids will have the largest effect on PPARα-
dependent gene transcription and subsequently increase lipid handling capacity 
in PBMC to the highest extend. Moreover, it has been found that activation of 
T-cells after pre-incubation with a PPARα ligand reduces expression of pro-
inflammatory cytokines31. Both, the cellular lipid handling and the balanced 
inflammatory response capacity, are of pivot importance in the development 
of diet-related chronic diseases such as metabolic syndrome, diabetes type II 
and atherosclerosis. Illustrative for this is that PPARα-specific agonists strongly 
inhibited atherosclerosis in mice studies54, 55. In addition, several clinical trials 
have shown that synthetic agonists of PPARα have beneficial, anti-atherogenic 
effects in humans56. We hypothesize that replacing dietary saturated fatty 
acids by dietary (poly)unsaturated fatty acid will activate PPARα, leading to 
an increased fat handling capacity and decreased pro-inflammatory response 
in PBMC, ultimately resulting in a decreased cell activation and consequent 
prevention of the onset of diet-related disorders such as atherosclerosis and 
metabolic syndrome. These results not only imply that PBMC can be used for 
further characterization of human PPARα, in vivo and ex vivo, but also that PBMC 
are good candidate cells to study other molecular mechanism of nutrients. In 
summary, we have shown that physiologically relevant metabolic conditions such 
as fasting are reflected by PBMC gene expression profiles. Therefore, these profiles 
show great potential to be used in the detection of even more subtle changes in 
gene expression as expected in nutritional intervention studies. Additionally, our 
intervention study showed that during fasting, when blood free fatty acids are 
increased, the fat handling capability of PBMC was augmented by an increase in 
fatty acid β-oxidation. Finally, our ex vivo study demonstrated a functional role 
of PPARα in human PBMC, suggesting that this nuclear factor regulates the lipid 
handling capacity of these cells, which probably can be regulated by the type of 
dietary fat intake. 
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Abstract
Background
Peripheral blood mononuclear cells (PBMCs) are relatively easily obtainable 
cells in humans. Gene expression profiles of PBMCs have been shown to reflect 
the pathological and physiological state of a person. Recently, we showed that the 
nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) has a 
functional role in human PBMCs during fasting. However, the extent of the role of 
PPARα in human PBMCs remains unclear. In this study, we therefore performed 
gene expression profiling of PBMCs incubated with the specific PPARα ligand 
WY14,643. 
Results
Incubation of PBMCs with WY14,643 for 12 hours resulted in a differential 
expression of 1,373 of the 13,080 genes expressed in the PBMCs. Gene expression 
profiles showed a clear individual response to PPARα activation between six 
healthy human blood donors. Pathway analysis showed that genes in fatty acid 
metabolism, primarily in β-oxidation were up-regulated upon activation of 
PPARα with WY14,643, and genes in several amino acid metabolism pathways 
were down-regulated.
Conclusions
This study shows that PPARα in human PBMCs regulates fatty acid and amino 
acid metabolism. In addition, PBMC gene expression profiles show individual 
responses to WY14,643 activation. We showed that PBMCs are a suitable model 
to study changes in PPARα activation in healthy humans. 
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Background
The function of the nuclear receptor peroxisome proliferator-activated receptor 
alpha (PPARα) has been studied extensively from the time of its discovery in the 
early 1990s57. PPARα is a ligand activated nuclear receptor, which is known to be 
activated by free fatty acids and their derivatives58, 59. Besides fatty acids, several 
synthetic compounds are available that specifically activate PPARα, including 
hypolipidemic drugs, such as fibrates and pirinixic acid (WY14,643)60. Synthetic 
PPARα agonists mimic effects of dietary unsaturated fatty acids on hepatic gene 
expression in terms of regulation of target genes and molecular mechanism61. 
Activation of PPARα with WY14,643 in mice showed that the main function of 
PPARα in liver is the regulation of lipid metabolism, and more specifically fatty 
acid β-oxidation62. PPARα was also found to be involved in regulation of amino 
acid metabolism63 and inflammation64, 65. In humans, the function of PPARα is 
examined less thoroughly, because functional studies are more complicated. 
There is no human genetic disease linked to a dysfunctional PPARα gene and tissue 
sampling is often not feasible in healthy volunteers. Blood is one of the few tissues 
which is readily available in healthy humans. Peripheral blood mononuclear 
cells (PBMCs) are relatively easily obtainable by isolation from blood. These cells 
consist of lymphocytes and monocytes/macrophages and it is known that PPARα 
is expressed in these cells31, 32. The use of PBMCs has proven to be highly robust 
in distinguishing a disease state from healthy state, by studying gene expression 
profiles of these cells7, 66. Recently, we showed that PBMC gene expression profiles 
of healthy volunteers can also reflect changes between 24 and 48 hours fasting, 
when plasma fatty acid concentrations are elevated. In addition, we showed that 
PPARα seems to have a functional role in human PBMC during fasting as several 
of the genes changed upon fasting were also changed upon incubation of PBMC 
with the specific PPARα agonist WY14,64367. However, the extent of the role of 
PPARα in human PBMCs remains unclear. Therefore, we tried to elucidate the 
function of PPARα in human PBMCs by whole genome microarray analysis of 
the PBMCs incubated with the specific PPARα ligand WY14,643. Furthermore, to 
examine the complete role of PPARα within PBMCs during fasting, we compared 
microarray analysis of PBMCs activated with WY14,643, with microarray analysis 
of PBMCs during 24 hours of fasting.
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Methods 
PBMC incubation
PBMCs from six healthy Caucasian male blood donors, aged between 30 and 48 yr, 
were isolated directly after arrival of the buffy coat (max. 8 hours after donation) 
by Ficol-paque Plus density gradient centrifugation (Amersham Biosciences, 
Roosendaal, the Netherlands). PBMCs were incubated in RPMI1640 medium 
with 2 mmol/L L-glutamine, 10% fetal bovine serum and antibiotics (penicillin 
and streptomycin) in the presence of 5% CO
2
 at 37°C. at 1.0 x 106 cells per ml 
with either WY14,643 (50 μM) or vehicle (DMSO, 0.1%) for 12 hours. All donors 
gave full written informed consent.
Pre- vs. postprandial incubation
PBMCs of four healthy volunteers, aged between 28 and 34, were isolated after 
a meal and after an overnight fast. PBMCs were incubated at 1.0 x 106 cells per 
ml with either WY14,643 (50 μM) or vehicle (DMSO, 0.1%) for 12 hours. All 
volunteers gave full written informed consent.
Statistical methods
A 2-tailed paired t test was used to determine significant differences in Q-PCR 
gene expression values between the postprandial and the fasted state. Statistical 
significance was accepted at p 0.05. All calculations were performed with the use 
of the SPSS (version 12.0.1; SPSS, Chicago, IL).
Microarray processing
For 6 donors of the incubation experiments, total RNA from PBMCs was labeled 
using a one-cycle cDNA labeling kit (Affymetrix Inc, Santa Clara, CA) and 
hybridized to Affymetrix Human whole genome U133 plus 2.0 arrays (Affymetrix). 
Sample labeling, hybridization to chips and image scanning was performed 
according to the manufacturer’s GeneChip Expression Analysis Technical Manual 
(Affymetrix).
Intervention study
For comparison of microarray data of the abovementioned incubation study, 
with microarray data of PBMC of fasted volunteers, we used the earlier described 
microarray data of a 48 hours fasting study67. Briefly, four healthy male Caucasian 
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volunteers, between 19 and 22 year of age were fasted for 48 hours. PBMCs 
were isolated out of blood taken at baseline, after 24 hours and after 48 hours of 
fasting. All volunteers gave full written informed consent and the study protocol 
was approved by the medical ethics committee of Wageningen University.
Microarray analysis
Microarrays were analyzed using the reorganized oligonucleotide probes as 
described by Dai et al (2005)68. Dai et al. combined all individual probes for a 
gene, enabling the possibility to detect the overall transcription activity of a 
gene, based on the latest genome and transcriptome information, instead of 
the Affymetrix probe set annotation. Application of this annotation procedure 
on the previously published data from the 48 hours fasting study67 resulted 
in a difference in number of genes expressed and changed as compared to the 
previously used annotation method as this analysis was performed on probe set 
level.
Expression values were calculated using the Robust Multichip Average (RMA) 
method. RMA signal value estimates are based on a robust average of background 
corrected perfect match intensities and normalization was performed using 
quantile normalization41, 42. Only genes with normalized signals higher then 
20 on at least two out of twelve arrays were defined as expressed and selected 
for further analysis. Genes were defined as ‘changed’ when comparison of the 
normalized signal intensities showed a p-value lower then 0.05 in a two-tailed 
paired t test with Bayesian correction (Limma)69. Pathway analysis was performed 
using Ingenuity Pathway Analysis 5.5 (Ingenuity Systems). Array data have been 
submitted to the Gene Expression Omnibus, accession number GSE11289.
PPRE incidence
To indicated which of the genes changed upon activation of PPARα had a 
predicted or reported peroxisome proliferator response element (PPRE), we used 
information from Lemay et al.70. This paper recently reported predicted PPRE on 
a genome wide scale, using computational genomics and also summarized known 
PPRE. Using Genomatix software71, network analysis was performed on 1,373 
genes in BiblioSphere, from which transcription factors were selected that were 
directly linked to more than 10 genes from our list of changed genes. Subsequent 
transcription factor binding site analysis identified transcription factor binding 
Activation of PPARα in human PBMCs | 43
sites in the promoters of our genes of interest that were cocited at least once in 
an abstract with these transcription factors. Heat maps were created by using 
Spotfire software.
cDNA synthesis and quantitative real-time PCR
RNA was reverse transcribed with the use of the cDNA synthesis kit (Promega, 
Leiden, the Netherlands). Standard quantitative real-time polymerase chain 
reaction (Q-PCR) was performed with the use of Platinum Taq DNA polymerase 
and SYBR Green on an iCycler PCR machine (Bio-Rad Laboratories BV) and 
duplicated at least twice. Primer sequences used in the PCRs were chosen based 
on the sequences available in PRIMERBANK72. Q-PCR data were normalized by 
measuring cycle threshold ratios between candidate genes and a housekeeping 
gene, human acidic ribosomal phosphoprotein PO, which was shown to be 
consistent within PBMCs45.
Results
PPARα regulation in PBMCs after incubation with WY14,643 
Incubation of PBMC with the specific PPARα ligand WY14,643 for 12 hours 
resulted in a differential expression of 1,373 of the 13,080 genes expressed in 
the PBMCs, indicating a PPARα-dependent regulation of 10.5% of the genes 
expressed in PBMC (Figure 1). More than half of these genes (56%) were up-
regulated. Pathway analysis of the genes changed upon activation of PPARα with 
WY14,643, showed a marked increase in fatty acid metabolism, primarily in β-
oxidation, and a decrease in several amino acid metabolism pathways (data not 
shown).
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Figure 1 Flow chart of the followed gene selection procedure after microarray analysis of WY14,643 
incubated PBMCs from 6 donors. PPRE; number of genes containing a peroxisome proliferator 
response element according to Lemay et al.
A peroxisome proliferator response elements (PPREs) was ascribed to 106 out 
of the 1,373 genes changed, using the study of Lemay et al70. Of these genes, 
75 were up-regulated and 31 were down-regulated (Figure 2). Figure 2 shows 
the responses to activation of PPARα for each person by illustrating the changes 
in gene expression of these 106 genes per individual. For several genes a clear 
variation in response upon PPARα activation between individuals is present. 
Donor B and, especially, donor E show an obvious distinction from the other 
donors. However, no difference could be found in the expression of PPARα 
between the donors at basal level, and also after incubation with WY14,643 no 
change in expression of PPARα was observed (data not shown).
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Figure 2 (right page) Heatmap of the signal log ratio of genes changed upon incubation with 
WY14,643 that contained a predicted or reported PPRE. Red indicates up-regulation compared 
to the vehicle incubated PBMCs and green indicates down-regulation. SLR, signal log ratio; PPRE, 
peroxisome proliferator response element.
Another reason for the variation could be the difference in concentration of the 
PPARα ligands, i.e. fatty acids, and other nutritional factors present in the blood 
during donation. Blood donors are commonly advised to eat before donating 
blood. To investigate whether the nutritional status influences changes in gene 
expression, we incubated PBMCs of four volunteers, obtained after a meal and 
after an overnight fast, with WY14,643. Using QPCR, we determined the changes 
in PBMC gene expression of genes that showed either a low (PDK4, SLC25A20, 
ACAA2) or a high variation (CPT1, ABCA1, TLR4, PPARγ) between donors in the 
microarray analyzes of the first study (Figure 3). No significant differences were 
observed in gene expression between the fasted and postprandial state.
Figure 3 Mean gene expression changes of PBMCs incubated with WY14,643, isolated postprandial 
or after an overnight fast. Error bars indicate standard deviations. PDK4, Pyruvate dehydrogenase 
kinase 4; SLC25A20, carnitine-acylcarnitine translocase; ACAA2, acetyl-Coenzyme A acyltransferase 
2; CPT1, Carnitine palmitoyltransferase 1; ABCA1, ATP binding cassette transporter 1; TLR4, Toll-like 
receptor-4; PPARγ, peroxisome proliferator-activated receptor gamma. 
To analyze whether the genes that did not have a PPRE according to Lemay 
et al. might have other transcriptional binding sites, a network analysis and a 
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Gene Name Gene Description Entrez ID Mean FC p-value PPRE SLR A SLR B SLR C SLR D SLR E SLR F
HAMP Hepcidin precursor (Liver-expressed antimicrobial peptide) 57817 -1.40 0.00076 predicted
PTX3 Pentraxin-related protein PTX3 precursor 5806 -1.31 0.00780 predicted
KCTD12 BTB/POZ domain-containing protein KCTD12 115207 -1.33 0.00037 predicted
ZEB2 Zinc finger E-box-binding homeobox 2 9839 -1.28 0.00794 predicted
PAK1IP1 p21-activated protein kinase-interacting protein 1 (PAK1-interacting protein 1) 55003 -1.21 0.03585 predicted
CCL23 Small inducible cytokine A23 precursor 6368 -1.20 0.01667 predicted
CCL19 Small inducible cytokine A19 precursor 6363 -1.20 0.02586 predicted
NR1H3 Oxysterols receptor LXR-alpha (Liver X receptor alpha) 10062 -1.23 0.00207 reported
RRAS Ras-related protein R-Ras precursor (p23) 6237 -1.16 0.01775 predicted
FZD2 Frizzled-2 precursor 2535 -1.23 0.01046 predicted
ATPAF1 ATP synthase mitochondrial F1 complex assembly factor 1 isoform 1 precursor 64756 -1.16 0.03081 predicted
FTSJ2 Putative ribosomal RNA methyltransferase 2 29960 -1.16 0.01201 predicted
TOB1 Tob1 protein (Transducer of erbB-2 1) 10140 -1.14 0.03696 predicted
HspBP1 Hsp70-binding protein 1 (Heat shock protein-binding protein 1) 23640 -1.13 0.02131 predicted
CD68 Macrosialin precursor (CD68 antigen) 968 -1.15 0.01269 predicted
PAQR4 Progestin and adipoQ receptor family member 4 124222 -1.12 0.04328 predicted
C14orf4 RING finger protein C14orf4 64207 -1.14 0.01352 predicted
MYADM Myeloid-associated differentiation marker 91663 -1.14 0.00947 predicted
MRPL48 39S ribosomal protein L48, mitochondrial precursor 51642 -1.11 0.03522 predicted
STAG3 Cohesin subunit SA-3 10734 -1.24 0.00449 predicted
MARVELD1 MARVEL domain containing 1 83742 -1.18 0.01274 predicted
PRRT2 proline-rich transmembrane protein 2 112476 -1.14 0.04240 predicted
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 23158 -1.18 0.00424 predicted
FAM35A Protein FAM35A 54537 -1.13 0.04945 predicted
NUP62 L-amino-acid oxidase precursor 259307 -1.10 0.03627 predicted
WTAP Wilms’ tumor 1-associating protein 9589 -1.11 0.03427 predicted
SGK2 Serine/threonine-protein kinase Sgk2 10110 -1.11 0.02416 predicted
CCNY Cyclin fold protein 1 (Cyclin box protein 1) 219771 -1.09 0.04023 predicted
DLEU1 deleted in lymphocytic leukemia,1 10301 -1.10 0.03335 predicted
PDF Peptide deformylase, mitochondrial precursor 64146 -1.09 0.04462 predicted
PDF Peptide deformylase, mitochondrial precursor 84342 -1.09 0.04462 predicted
IQCG IQ domain-containing protein G 84223 1.01 0.03782 predicted
GBA2 Non-lysosomal glucosylceramidase 57704 1.12 0.02249 predicted
TGFBR2 TGF-beta receptor type-2 precursor 7048 1.13 0.02284 predicted
SLC25A28 Mitoferrin-2 (Mitochondrial iron transporter 2) 81894 1.14 0.00979 predicted
NISCH nischarin 11188 1.17 0.00321 predicted
FASTK Fas-activated serine/threonine kinase 10922 1.12 0.02913 predicted
POLD4 DNA polymerase subunit delta 4 57804 1.11 0.03927 predicted
FGR Proto-oncogene tyrosine-protein kinase FGR 2268 1.14 0.01256 predicted
CLDN15 Mitochondrial fission 1 protein 24146 1.13 0.02469 predicted
GPS2 G protein pathway suppressor 2 2874 1.17 0.01149 predicted
TMEM43 Transmembrane protein 43 79188 1.16 0.04998 predicted
TAPBP Tapasin precursor 6892 1.18 0.03900 predicted
GPR174 Probable G-protein coupled receptor 174. 84636 1.12 0.03679 predicted
LINS1 lines homolog 1 55180 1.19 0.01190 predicted
POLG2 DNA polymerase subunit gamma 2 11232 1.19 0.00451 predicted
LOC168455 hypothetical protein LOC168455 168455 1.19 0.00392 predicted
HIFPH4 Putative HIF-prolyl hydroxylase PH-4 54681 1.14 0.01885 predicted
C1orf162 Uncharacterized protein C1orf162. 128346 1.19 0.00462 predicted
NPHP4 Nephrocystin-4 (Nephroretinin). 261734 1.23 0.00317 predicted
OTUD5 OTU domain-containing protein 5. 55593 1.11 0.01592 predicted
ARIH2 Protein ariadne-2 homolog 10425 1.12 0.01439 predicted
U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 4 isoform 2 199746 1.13 0.02068 predicted
AKAP8L A-kinase anchor protein 8-like ( 26993 1.13 0.00936 predicted
CYP27B1 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial precursor 1594 1.15 0.00400 predicted
CBY1 Protein Chibby 25776 1.18 0.00107 predicted
PPARG Peroxisome proliferator-activated receptor gamma 5468 1.20 0.00669 predicted
MITF Microphthalmia-associated transcription factor 4286 1.15 0.00643 predicted
TXNIP Thioredoxin-interacting protein 10628 1.15 0.00553 predicted
KIAA0467 Uncharacterized protein KIAA0467 23334 1.18 0.00250 predicted
CXCL16 Small inducible cytokine B16 precursor 58191 1.17 0.00739 predicted
VMO1 Vitelline membrane outer layer protein 1 homolog precursor 284013 1.20 0.00200 predicted
GPIBb glycoprotein Ib beta polypeptideprecursor 2812 1.18 0.02852 predicted
INSIG1 Insulin-induced gene 1 protein 3638 1.13 0.04718 non DR1
SCML1 Sex comb on midleg-like protein 1 6322 1.13 0.04360 predicted
ACRC ACRC protein 93953 1.21 0.01719 predicted
TLR4 Toll-like receptor 4 precursor 7099 1.23 0.00938 predicted
C15orf17 Uncharacterized protein C15orf17 57184 1.16 0.02275 predicted
ERRFI1 ERBB receptor feedback inhibitor 1 54206 1.19 0.00438 predicted
ZMAT1 zinc finger, matrin type 1 isoform 1 84460 1.18 0.00535 predicted
TESK2 Dual specificity testis-specific protein kinase 2 10420 1.20 0.00694 predicted
AKT1S1 Proline-rich AKT1 substrate 1 84335 1.23 0.00185 predicted
BACH1 Transcription regulator protein BACH1 571 1.19 0.00544 predicted
G0S2 Putative lymphocyte G0/G1 switch protein 2 50486 1.25 0.00540 predicted
MBOAT5 Membrane-bound O-acyltransferase domain-containing protein 5 10162 1.26 0.00282 predicted
ABCA1 ATP-binding cassette sub-family A member 1 19 1.32 0.00030 reported
CD36 Leukocyte differentiation antigen CD36 948 1.29 0.03259 predicted
CYP1A1 Cytochrome P450 1A1 1543 1.26 0.02995 predicted
CLCF1 Cardiotrophin-like cytokine factor 1 precursor 23529 1.15 0.04082 predicted
CAPN3 Neutral alpha-glucosidase C 825 1.18 0.00492 predicted
SMAD3 Mothers against decapentaplegic homolog 3 4088 1.23 0.00127 predicted
MMP19 Matrix metalloproteinase-19 precursor 4327 1.22 0.01219 predicted
CPT1B Carnitine O-palmitoyltransferase I, muscle isoform 1375 1.23 0.00272 predicted
ATHL1 acid trehalase-like 1 80162 1.27 0.00362 predicted
AP1G2 Junctophilin-4 (Junctophilin-like 1 protein). 8906 1.19 0.00136 predicted
USP52 PAB-dependent poly(A)-specific ribonuclease subunit 2 9924 1.27 0.00012 predicted
TSPYL2 TSPY-like 2 64061 1.21 0.00472 predicted
LOC54540 hypothetical protein LOC54540 54540 1.27 0.00049 predicted
PLA2G4B Cytosolic phospholipase A2 beta 8681 1.16 0.02102 predicted
IL11RA Interleukin-11 receptor alpha chain precursor 3590 1.19 0.02288 predicted
SLC25A34 solute carrier family 25, member 34 284723 1.22 0.00967 predicted
VEGFA Vascular endothelial growth factor A precursor 7422 1.22 0.00807 predicted
TANFKBH T-cell activation NFKB-like protein 84807 1.29 0.00236 predicted
TMEM185A Transmembrane protein 185A 84548 1.25 0.01367 predicted
NXF1 Nuclear RNA export factor 1 10482 1.35 0.00047 predicted
CSAD Cysteine sulfinic acid decarboxylase 51380 1.37 0.00238 predicted
CYorf15B lipopolysaccaride-specific response 5-like protein 84663 1.42 0.00046 predicted
TPP1 Tripeptidyl-peptidase 1 precursor 1200 1.40 0.03811 predicted
SFRS16 Splicing factor, arginine/serine-rich 16 11129 1.44 0.02157 predicted
TMEM135 Transmembrane protein 135 65084 1.66 0.00142 predicted
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial (Acetyl-CoA acyltransferase) 10449 1.46 0.00002 predicted
SLC25A20 Mitochondrial carnitine/acylcarnitine carrier protein (Carnitine/acylcarnitine translocase) 788 1.52 0.00000 reported
ACADVL Very-long-chain specific acyl-CoA dehydrogenase, mitochondrial precursor 37 2.06 0.00000 predicted
ADFP Adipophilin (Adipose differentiation-related protein) 123 3.78 0.00000 reported
PDK4 Pyruvate dehydrogenase kinase 4 5166 4.72 0.00000 reported
FABP4 Fatty acid-binding protein, adipocyte 2167 13.89 0.01455 reported
subsequent transcription factor binding site search with Genomatix software was 
performed. The network analysis showed that, besides the transcription factor 
PPAR, the transcription factors NFkB, JUN, TP53, SP1 and CTNNB1 were also 
directly linked to at least 10 genes from the list of 1,373 genes, The subsequent 
search for binding sites resulted in an additional 122 genes that could be linked 
to a PPRE and revealed that another 371 genes could be linked to at least one of 
the other selected transcription factors (Additional file).
To obtain a selection of robust responding genes upon activation of PPARα with 
WY14.643, genes were selected that were more than 10% up or down regulated 
in all donors . This resulted in a list of 58 genes, including several known PPARα 
target genes (ADFP, PDK4, SLC25A20) (Figure 4), with a main function in fatty 
acid β-oxidation. Remarkably, only 16 % of the genes in this list contained a 
predicted or reported PPRE. 
Gene Name Gene Description Mean FC p value Entrez ID PPRE SLR A SLR B SLR C SLR D SLR E SLR F
ADFP Adipose differentiation-related protein 3.78 2.86E-10 123 reported
PDK4 Pyruvate dehydrogenase kinase isozyme 4 4.72 6.16E-07 5166 reported
ACADVL Very-long-chain specific acyl-CoA dehydrogenase 2.06 1.05E-07 37 predicted
LY6G5B Casein kinase II subunit beta 1.88 4.82E-05 58496 -
LOC283874 Hypothetical protein FLJ20393 1.66 8.72E-05 283874 -
SLC25A20 Mitochondrial carnitine/acylcarnitine carrier protein 1.52 8.68E-07 788 reported
IMPA2 Inositol monophosphatase 2 1.47 1.01E-05 3613 -
C21orf7 TAK1-like protein. 1.40 1.79E-04 56911 -
ST14 Suppressor of tumorigenicity protein 14 1.60 2.84E-05 6768 -
HS3ST1 Heparan sulfate glucosamine 3-O-sulfotransferase 1 1.51 2.55E-04 9957 -
ETFDH Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 1.42 1.32E-04 2110 -
MICALL2 MICAL-like protein 2. 1.36 1.65E-04 79778 -
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 1.60 2.35E-04 1326 -
TMEM135 Transmembrane protein 135. 1.66 1.42E-03 65084 predicted
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 1.46 2.37E-05 10449 predicted
BZRAP1 Peripheral-type benzodiazepine receptor-associated protein 1 1.36 2.93E-05 9256 -
ABCC3 Canalicular multispecific organic anion transporter 2 1.34 9.88E-05 8714 -
LOC158830 similar to Ab2-183 1.41 1.51E-04 158830 -
C20orf119 Polyadenylate-binding protein 1-like. 1.40 2.80E-04 80336 -
PPP1R3E Homeobox and leucine zipper protein Homez 1.31 1.29E-04 90673 -
PILRB paired immunoglobulin-like type 2 receptor beta isoform b 1.32 1.58E-04 29990 -
HBEGF Heparin-binding EGF-like growth factor 1.36 7.70E-05 1839 -
CXCL2 Macrophage inflammatory protein 2-alpha 1.31 6.44E-04 2920 -
CCDC17 coiled-coil domain containing 17 1.25 6.35E-04 149483 -
CYorf15B lipopolysaccaride-specific response 5-like protein 1.42 4.61E-04 84663 predicted
NLRC4 Caspase recruitment domain-containing protein 12 1.36 3.15E-04 58484 -
USP52 PAB-dependent poly(A)-specific ribonuclease subunit 2 1.27 1.17E-04 9924 predicted
FNBP4 formin binding protein 4 1.29 3.83E-04 23360 -
COG3 Conserved oligomeric Golgi complex component 3 1.23 6.07E-04 83548 -
CD300A CMRF35-H antigen precursor 1.26 5.91E-04 11314 -
ABCC5 Multidrug resistance-associated protein 5 1.24 9.97E-04 10057 -
CREBZF CREB/ATF bZIP transcription factor 1.26 2.51E-03 58487 -
MPP7 palmitoylated membrane protein 7 1.24 8.44E-04 143098 -
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 1.23 1.38E-03 1891 -
DEADC1 deaminase domain containing 1 1.20 5.78E-04 134637 -
CLK2 Dual specificity protein kinase CLK2 1.19 1.52E-03 1196 -
TTRAP TRAF and TNF receptor-associated protein 1.23 1.15E-03 51567 -
SPG7 Paraplegin 1.19 9.28E-04 6687 -
MTX3 metaxin 3 1.14 5.25E-03 345778 -
CCDC130 Coiled-coil domain-containing protein 130 1.20 1.18E-03 81576 -
CBY1 Protein Chibby 1.18 1.07E-03 25776 predicted
SYTL1 Synaptotagmin-like protein 1 1.17 1.75E-03 84958 -
C6orf70 Uncharacterized protein C6orf70 1.17 2.19E-03 55780 -
GPNMB Transmembrane glycoprotein NMB -1.41 9.23E-06 10457 -
EMR1 EGF-like module-containing mucin-like hormone receptor-like 1 -1.38 1.30E-05 2015 -
ANXA3 Annexin A3 -1.42 3.57E-05 306 -
TMEM176A Transmembrane protein 176A -1.29 4.95E-05 55365 -
CAPG Macrophage-capping protein -1.30 1.06E-04 822 -
DPYSL2 Dihydropyrimidinase-related protein 2 -1.38 6.02E-05 1808 -
IGSF6 immunoglobulin superfamily, member 6 -1.31 2.52E-04 10261 -
IFI6 Interferon-induced protein 6-16 -1.32 3.05E-04 2537 -
ADORA3 Adenosine A3 receptor -1.34 8.81E-04 140 -
C1orf115 Uncharacterized protein C1orf115. -1.23 2.82E-04 79762 -
TRIP10 Cdc42-interacting protein 4 -1.20 9.05E-04 9322 -
FPR1 fMet-Leu-Phe receptor -1.22 5.83E-04 2357 -
TNFRSF8 Tumor necrosis factor receptor superfamily member 8 -1.18 2.37E-03 943 -
GAS2L1 GAS2-like protein 1 -1.18 1.18E-03 10634 -
C1orf163 Hcp beta-lactamase-like protein C1orf163. -1.18 1.43E-03 65260 -
Figure 4 (left page) Heat map of genes changed more than 10% in all individuals after incubation 
with WY14,643. Red indicates up-regulation and green indicates down-regulation. SLR, signal log 
ratio; PPRE, peroxisome proliferator response element 
To validate our data observed with microarray analyzes a selection of genes 
changed in the microarray analyzes was also measured with quantitative real 
time PCR (Q-PCR). In concordance with our microarray results, Q-PCR analyzes 
resulted in similar changes in expression of all genes analyzed (Figure 5). 
Figure 5 Mean gene expression changes of microarray and quantitative real time PCR analysis 
(Q-PCR) of six genes after incubation with WY14,643. Error bars indicated standard deviations. 
PDK4, Pyruvate dehydrogenase kinase 4; ACADVL, acyl-Coenzyme A dehydrogenase, very long chain; 
ABCA1, ATP binding cassette transporter 1; SLC25A20, carnitine-acylcarnitine translocase; ACAA2, 
acetyl-Coenzyme A acyltransferase 2.
PPARα regulation in PBMCs during fasting 
Figure 6 shows the genes changed upon 24 hours fasting in healthy human 
volunteers with the number of genes that contain a PPRE. Comparison of gene 
expression profiles of PBMCs incubated with the PPARα ligand WY14,643 and 
fasted for 24 hours resulted in an overlap of 238 genes, indicating that around 
14 % of the genes changed during fasting are regulated by PPARα (Figure 7). 
Pathway analysis showed that these 238 genes were primarily involved in fatty 
acid metabolism. We found no overlap in pathways involved in amino acid 
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Gene Name Gene Description Mean FC p value Entrez ID PPRE SLR A SLR B SLR C SLR D SLR E SLR F
ADFP Adipose differentiation-related protein 3.78 2.86E-10 123 reported
PDK4 Pyruvate dehydrogenase kinase isozyme 4 4.72 6.16E-07 5166 reported
ACADVL Very-long-chain specific acyl-CoA dehydrogenase 2.06 1.05E-07 37 predicted
LY6G5B Casein kinase II subunit beta 1.88 4.82E-05 58496 -
LOC283874 Hypothetical protein FLJ20393 1.66 8.72E-05 283874 -
SLC25A20 Mitochondrial carnitine/acylcarnitine carrier protein 1.52 8.68E-07 788 reported
IMPA2 Inositol monophosphatase 2 1.47 1.01E-05 3613 -
C21orf7 TAK1-like protein. 1.40 1.79E-04 56911 -
ST14 Suppressor of tumorigenicity protein 14 1.60 2.84E-05 6768 -
HS3ST1 Heparan sulfate glucosamine 3-O-sulfotransferase 1 1.51 2.55E-04 9957 -
ETFDH Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 1.42 1.32E-04 2110 -
MICALL2 MICAL-like protein 2. 1.36 1.65E-04 79778 -
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 1.60 2.35E-04 1326 -
TMEM135 Transmembrane protein 135. 1.66 1.42E-03 65084 predicted
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 1.46 2.37E-05 10449 predicted
BZRAP1 Peripheral-type benzodiazepine receptor-associated protein 1 1.36 2.93E-05 9256 -
ABCC3 Canalicular multispecific organic anion transporter 2 1.34 9.88E-05 8714 -
LOC158830 similar to Ab2-183 1.41 1.51E-04 158830 -
C20orf119 Polyadenylate-binding protein 1-like. 1.40 2.80E-04 80336 -
PPP1R3E Homeobox and leucine zipper protein Homez 1.31 1.29E-04 90673 -
PILRB paired immunoglobulin-like type 2 receptor beta isoform b 1.32 1.58E-04 29990 -
HBEGF Heparin-binding EGF-like growth factor 1.36 7.70E-05 1839 -
CXCL2 Macrophage inflammatory protein 2-alpha 1.31 6.44E-04 2920 -
CCDC17 coiled-coil domain containing 17 1.25 6.35E-04 149483 -
CYorf15B lipopolysaccaride-specific response 5-like protein 1.42 4.61E-04 84663 predicted
NLRC4 Caspase recruitment domain-containing protein 12 1.36 3.15E-04 58484 -
USP52 PAB-dependent poly(A)-specific ribonuclease subunit 2 1.27 1.17E-04 9924 predicted
FNBP4 formin binding protein 4 1.29 3.83E-04 23360 -
COG3 Conserved oligomeric Golgi complex component 3 1.23 6.07E-04 83548 -
CD300A CMRF35-H antigen precursor 1.26 5.91E-04 11314 -
ABCC5 Multidrug resistance-associated protein 5 1.24 9.97E-04 10057 -
CREBZF CREB/ATF bZIP transcription factor 1.26 2.51E-03 58487 -
MPP7 palmitoylated membrane protein 7 1.24 8.44E-04 143098 -
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 1.23 1.38E-03 1891 -
DEADC1 deaminase domain containing 1 1.20 5.78E-04 134637 -
CLK2 Dual specificity protein kinase CLK2 1.19 1.52E-03 1196 -
TTRAP TRAF and TNF receptor-associated protein 1.23 1.15E-03 51567 -
SPG7 Paraplegin 1.19 9.28E-04 6687 -
MTX3 metaxin 3 1.14 5.25E-03 345778 -
CCDC130 Coiled-coil domain-containing protein 130 1.20 1.18E-03 81576 -
CBY1 Protein Chibby 1.18 1.07E-03 25776 predicted
SYTL1 Synaptotagmin-like protein 1 1.17 1.75E-03 84958 -
C6orf70 Uncharacterized protein C6orf70 1.17 2.19E-03 55780 -
GPNMB Transmembrane glycoprotein NMB -1.41 9.23E-06 10457 -
EMR1 EGF-like module-containing mucin-like hormone receptor-like 1 -1.38 1.30E-05 2015 -
ANXA3 Annexin A3 -1.42 3.57E-05 306 -
TMEM176A Transmembrane protein 176A -1.29 4.95E-05 55365 -
CAPG Macrophage-capping protein -1.30 1.06E-04 822 -
DPYSL2 Dihydropyrimidinase-related protein 2 -1.38 6.02E-05 1808 -
IGSF6 immunoglobulin superfamily, member 6 -1.31 2.52E-04 10261 -
IFI6 Interferon-induced protein 6-16 -1.32 3.05E-04 2537 -
ADORA3 Adenosine A3 receptor -1.34 8.81E-04 140 -
C1orf115 Uncharacterized protein C1orf115. -1.23 2.82E-04 79762 -
TRIP10 Cdc42-interacting protein 4 -1.20 9.05E-04 9322 -
FPR1 fMet-Leu-Phe receptor -1.22 5.83E-04 2357 -
TNFRSF8 Tumor necrosis factor receptor superfamily member 8 -1.18 2.37E-03 943 -
GAS2L1 GAS2-like protein 1 -1.18 1.18E-03 10634 -
C1orf163 Hcp beta-lactamase-like protein C1orf163. -1.18 1.43E-03 65260 -
metabolism. Exploration of the genes involved in fatty acid metabolism showed 
that fatty acid β-oxidation was specifically regulated, both in WY14,643 incubated 
cells and in PBMCs isolated after fasting (data not shown).
Figure 6 Flow chart of the followed gene selection procedure after microarray analysis of PBMC of 
three 24 hour fasted subjects. PPRE; number of genes containing a peroxisome proliferator response 
element according to Lemay et al. Data from this fasting study was published previously67, but has 
been used here after applying a different annotation procedure.
Figure 7 Venn diagram of overlap between genes changed upon WY14,643 incubation and after 24 
hours fasting. 
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Discussion 
In the present study, we showed that activation of the nuclear receptor PPARα 
in peripheral blood mononuclear cells results in a considerable change in gene 
expression profiles, as 10.5% of the genes expressed exhibited altered gene 
expression levels after incubation with the specific PPARα agonist WY14,643. 
The main function of PPARα in PBMCs appeared to be the regulation of fatty acid 
β-oxidation and other lipid metabolism related functions, which is in line with 
results from mice studies in liver36 and intestine73, and human cell line studies74, 75. 
Moreover, the observed down-regulation of amino acid metabolism has been 
shown before in liver in studies comparing wild type mice to the PPARα knock 
out mouse model63.
Besides the possible roles of PPARα in PBMCs, this study also demonstrates 
strong individual variability between the subjects in gene expression responses 
to activation with WY14,643. It appears that each donor has its own specific 
gene expression profile response to PPARα activation, which results in distinct 
differences in the expression of certain genes after WY14,643 incubation. Beck 
et al. also reported differences in responsiveness in gene expression between 
individuals, after incubation of endothelial cells with LPS. However, endothelial 
cell cultures were already divided beforehand into type I or type II responders 
based on their LPS mediated IL8 production76. In another study, incubation 
of cultured macrophages with oxidized low-density lipoprotein resulted in a 
person-specific inflammatory gene expression response that could be correlated 
to changes in gene expression of scavenger receptors77. However, we did 
not find a correlation between basal PPARα expression or changes in PPARα 
expression and the observed variation in gene expression changes. In addition, 
the differences observed are probably not caused by the nutritional status of the 
subjects at baseline, as we did not observe differences in expression changes 
of selected PPARα target genes between the postprandial and the fasted state 
of PBMCs incubated with WY14,643. However, it should be noted here that 
only four subjects were studied. A reason for the difference in response of the 
donors in the first study could be genetic variation, such as single nucleotide 
polymorphisms (SNPs) in the PPARα gene, its target genes or PPARα co-factors 
involved in activation of gene transcription. Furthermore, epi-genetic variation 
such as methylation status of the PPARα promoter or its target genes may have 
caused between-subject differences in gene expression levels. Additional studies 
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are required to elucidate whether gene expression profiles can be clustered in 
different response profiles, simplifying the identification of factors responsible 
for these individual responses. With respect to personalized nutrition these 
individual responses are of great interest as it can be expected that nutrients 
such as fatty acids can induce similar variations in response as WY14,643, which 
in the end might lead to personalized dietary advice.
The PPRE analyzes of the genes changed showed that approximately 8% of the 
genes changed after incubation with the PPARα ligand WY14,643 contained a 
predicted or reported PPRE, using the list as described by Lemay et al70. However, 
Lemay et al. report that they tolerate a low false-positive, and a high (60%) 
false-negative rate, suggesting that their list of PPREs is far from complete. Our 
additional transcription factor binding site analysis increase the number of 
genes that contain a PPRE to a total of 17% of the genes changed. A network 
search showed that, besides PPAR, five other transcription factors were involved 
in direct regulation of at least 10 out of the 1,373 changed genes. Interestingly, 
all these transcription factors are known to be affected by PPARα activation78-82. 
Transcription factor binding site analysis revealed that, out of the changed genes 
that did not contain a PPRE, 27% contained a binding site for at least one of the 
other five selected transcription factors These genes appear not to be regulated by 
PPARα directly, but indirectly, via these other transcription factors, a mechanism 
which has been suggested before83, 84. The role of PPARα in this respect seems 
to be extensively larger than expected based on the outcome of PPRE analyzes 
alone. 
An interesting observation is the decrease in expression level of genes containing 
a PPRE. Activation of PPARα by a ligand may result in a negative regulation of 
genes by means of transrepression as has been reported in several studies and 
reviewed by Ricote and Glass (2007)23. This transrepression, however, does 
not require the presence of PPREs in the promoter regions of the target genes. 
Apparently, negative regulation of these genes, regardless of its mechanism, is 
stronger than the transcriptional activation of PPARα. Previously, Degenhardt et 
al. (2006) also showed down regulation of an insulin-like growth factor-binding 
protein gene (IGFBP-6) that contained a predicted PPRE, in response to the 
presence of a PPARα ligand85. 
The overlap in gene expression profiles between fasting and incubation with 
WY14,643 shows that PPARα in PBMCs carries out a substantial part of its 
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function during fasting, when concentrations of its natural ligands, free fatty 
acids, are elevated in the blood. The main role of PPARα in PBMCs during fasting 
is fatty acid β-oxidation, most likely to cope with the reduced availability of 
glucose for utilization in energy production and the increase of fatty acids. 
Direct comparison between the two array analysis should be examined with care, 
since the two studies are distinctly different in set-up. The fasting intervention 
study was conducted in vivo, while the WY14,643 incubation experiments were 
performed ex vivo. Moreover, fasting involves many more changes in physiology, 
apart from the before-mentioned increase in plasma free fatty acids, including 
changes in plasma insulin, glucose and leptin concentrations. The PPARα ligand 
incubations were set-up to elucidate the specific effects of activation of one 
nuclear factor, controlling for all other parameters. 
Summarizing, this study gives us valuable information on the extent of the effect of 
PPARα activation, during fasting and in general, on human PBMC gene expression. 
It also shows that persons respond differently to PPARα activation with respect 
to their gene expression changes, indicating a possible person-specific nutrient 
response. It seems justified to conclude that human PBMCs are a suitable model 
to study changes in PPARα activation. This opens up the possibilities for more 
specific PPARα signaling studies in healthy humans using these relatively easily 
obtainable blood cells. 
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Presence of transcription factor binding sites in the genes changed in PBMC after 
incubation with WY14,643. Transcription factors were selected if they directly 
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affected at least 10 genes that were changed after WY14,643 incubation, in a 
network search using BiblioSphere (Genomatix). FC, fold change; PPRE (Lemay), 
peroxisome proliferator response element according to Lemay et al.70; NFkB, 
Nuclear factor kappa B binding site; JUN, Jun oncogene binding site; TP53, Tumor 
protein 53 binding site; SP1, Specificity protein 1 binding site; CTNNB1, catenin 
beta 1 binding site. Red indicates up regulated, green indicates down regulated.
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Abstract
Gene expression profiles of peripheral blood mononuclear cells (PBMCs) have 
been shown to reflect the pathological state of an individual, and we recently 
showed that these cells can also reflect physiological changes. However, little is 
known about the effects of nutrition on PBMC gene expression profiles. Nutrients 
such as polyunsaturated fatty acids (PUFAs) are known to elicit effects through 
gene transcription changes via activation of transcription factors, such as 
peroxisome proliferator-activated receptors. Therefore, we examined the effects 
of supplementation with the PUFAs EPA/DHA on whole genome PBMC gene 
expression profiles in healthy Dutch elderly, participating in a double-blind trial. 
Individuals were randomly assigned to consume 1.8 gram/day of EPA/DHA, 0.4 
gram/day of EPA/DHA or high oleic acid sunflower oil (HOSF) in capsules for 
26 weeks. Microarray analysis was performed on PBMC RNA from subjects who 
received high EPA/DHA (n=23) or HOSF capsules (n=25). Q-PCR was performed 
on the high EPA/DHA group (n=36), low EPA/DHA group (n=37) and the HOSF 
group (n=37). High EPA/DHA intake resulted in a change of 1040 genes and 
HOSF intake resulted in 298 genes changed. EPA/DHA intake showed lowered 
expression of genes in inflammatory and atherogenic related pathways, such as 
NF-κB signaling, eicosanoid synthesis, scavenger receptors activity, adipogenesis 
and hypoxia signaling. These results reveal that intake of EPA/DHA for 26 weeks 
alters gene expression profiles of PBMCs to a more anti-inflammatory status. 
Moreover, this nutrigenomics study demonstrates that PBMC profiling can not 
only reflect pathological conditions or physiological state, but can also mimic 
nutritional changes. 
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Introduction
The last few years there has been increasing interest in the use of gene expression 
profiles of peripheral blood mononuclear cells (PBMCs) as diagnostic biomarkers 
for the pathological state8, 86. The reason for this interest is the relatively simple 
accessibility of blood cells compared with other tissues in humans. We recently 
showed that, besides their usefulness to reveal disease states, these cells can also 
reflect physiological changes, such as fasting67. However, although some studies 
have been performed recently87, still little is known about the effects of nutrition 
on PBMCs gene expression profiles. Nutrients known to elicit effects on gene 
expression are fatty acids, which act mainly through activation of transcription 
factors, such as peroxisome proliferator-activated receptors (PPARs)88. These 
nuclear receptors are known to up- and down-regulate expression of genes 
involved in lipid metabolism and inflammation, respectively. Three types of PPARs 
have been identified; alpha, gamma and delta/beta24, which all have specific roles 
in different tissues. We have recently shown that PPARα has a functional role 
in human PBMCs89. The strongest natural ligands for PPARs are long chained 
polyunsaturated fatty acids (PUFAs), such as the n-3 PUFAs docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA)90, which are abundantly present 
in fatty fish. N-3 PUFA are therefore good candidates to explore the effects of 
nutrition on PBMC gene expression profiling. We examined the effects of EPA/
DHA supplementation for 26 weeks on whole genome PBMC gene expression 
profiles in a Dutch elderly population and compared the effects to a control 
supplementation of high oleic acid sunflower oil (HOSF).
PUFA effects on whole genome expression in humans | 9
Methods
Subjects
Healthy men and women of 65 years and over were screened and recruited 
according to the following exclusion criteria: current or recent (<4 weeks) use 
of fish oil supplements or intake of fish more than four times per week or more 
than 800 mg of EPA-DHA from fish per day as estimated by a fish consumption 
questionnaire, serious liver disease, consumption of more than 4 glasses of alcohol 
per day, unable to participate as judged by the responsible medical physician, 
allergy to fish(oil), swallowing problems, or participation in another clinical trial 
less than 2 months before the start of the trial or at the same time. Additionally, 
compliance to capsule use during a 2-week placebo run-in period had to be at 
least 80% on basis of self-report. 302 Subjects were included in the study and 
detailed baseline characteristics of these participants have been described 
elsewhere91. From these participants, 111 subjects were randomly included in 
the present study. All subjects gave written informed consent to participate in the 
study and the study protocol was approved by the Medical Ethical Committee of 
Wageningen University, the Netherlands.
Study design 
Subjects were randomly allocated to receive a daily dose of fish oil containing 
either a low dose of 0.4 g EPA/DHA, a high dose of 1.8 g EPA/DHA, or a high 
oleic acid sunflower oil (HOSF) for a period of 26 weeks (Lipid Nutrition/ Loders 
Croklaan, Wormerveer, the Netherlands). The oils were administered in six 
soft gelatin capsules daily, each containing 900 mg oil and 2.7 mg tocopherol 
as antioxidant (Banner Pharmacaps Europe B.V., Tilburg, the Netherlands). The 
fatty acid composition of the capsules was measured in 20 capsules taken at 
regular times during the study.
Blood sampling and PBMC isolation 
Fasting venous blood samples were collected at baseline and after 26 weeks of 
intervention. A blood sample for determination of n-3 PUFAs was collected into 
10 ml EDTA-vacutainers, immediately placed on ice, centrifuged at 2000 g at 
a temperature of 4 °C and then stored at -80 °C until laboratory analyses. N-3 
PUFAs in plasma cholesteryl esters were determined as described previously92. 
For PBMC isolation 4 ml of blood was collected in BD Vacutainer Cell Preparation 
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Tubes with sodium citrate (BD, Breda, The Netherlands). PBMCs were isolated 
immediately after blood collection according to the manufacturer’s manual.
Total RNA isolation
PBMC RNA was isolated from all PBMC samples using Qiagen RNeasy Micro kit 
(Qiagen, Venlo, the Netherlands). RNA yield was quantified on a Nanodrop ND 
1000 spectrophotometer (Nanodrop technologies, Wilmington, Delaware USA) 
and integrity was measured on an Agilent 2100 Bioanalyzer with RNA 6000 
Nano chips (Agilent Technologies, South Queensferry, UK).
Microarray processing
PBMC samples from 77 subjects yielded enough RNA to perform microarray 
analysis. De-blinding revealed that 25 subjects were in the high EPA/DHA group, 
26 in the low EPA/DHA group and 26 in the HOSF group. Microarray analysis 
was performed on baseline samples and samples after 26 weeks of intervention 
in the high EPA/DHA group and the HOSF group. Total RNA from PBMCs of these 
51 subjects was labeled using a one-cycle cDNA labeling kit (MessageAmpTM 
II-Biotin Enhanced Kit, Ambion, Inc.) and hybridized to human whole genome 
NuGO GeneChip arrays encoding 17,699 genes, designed by the European 
Nutrigenomics Organisation (NuGO) and manufactured by Affymetrix (Affymetrix 
Inc, Santa Clara, CA). Sample labeling, hybridization to chips and image scanning 
was performed according to the manufacturer’s GeneChip Expression Analysis 
Technical Manual (Affymetrix).
Microarray analysis
Microarrays from three subjects, 2 from the high EPA/DHA group and 1 from 
the HOSF group, were excluded because they did not fulfill our quality control 
criteria. Microarrays were analyzed using the reorganized oligonucleotide 
probes as described by Dai et al (2005)68. Expression values were calculated 
using the Robust Multichip Average (RMA) method. RMA signal value estimates 
are based on a robust average of background corrected perfect match intensities 
and normalization was performed using quantile normalization42. Only genes 
with normalized signals higher than 20 on at least 10 arrays were defined as 
‘expressed’ and selected for further analysis. Genes were defined as ‘changed’ 
when comparison of the normalized signal intensities showed a false discovery 
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rate Q-value93 lower than 0.05 in a two-tailed paired t test with Bayesian 
correction (Limma) (69). Pathway analysis was performed using GenMAPP 2.1, 
Ingenuity Pathway Analysis 5.5 (IPA), and Gene Set Enrichment Analysis 2.0.1 
(GSEA)94. 
cDNA synthesis and real time PCR
RNA from all subjects was reverse transcribed with use of a cDNA synthesis kit 
(Promega, Leiden, the Netherlands). Standard quantitative real-time polymerase 
chain reaction (Q-PCR) was performed with use of Platinum Taq DNA polymerase 
and SYBR Green on an iCycler PCR machine (Bio-Rad Laboratories BV) and 
duplicated at least twice. Primer sequences used in the PCRs were chosen 
based on the sequences available in PRIMERBANK (http://pga.mgh.harvard.
edu/ primerbank/index.html). Q-PCR data were normalized by measuring cycle 
threshold ratios between candidate genes and a housekeeping gene, human 
ribosomal protein LP0.
Statistical Analysis
Differences between baseline and end values of plasma metabolites and Q-PCR 
results were tested using a paired t-test and differences between groups were 
tested using ANOVA in the statistical package SPSS 12.0.1 (Chicago, Illinois). 
Statistical significance was accepted at p<0.05. Pathways were defined as 
significantly changed when p<0.05 (IPA and GSEA) or the z-score was higher 
than 1 (GenMAPP).
Results
Subject characteristics
From the 302 participants who were enrolled in the study, blood samples where 
randomly collected from 111 healthy men and woman varying in age from 66 
to 80 years old. A subset of these samples was used to perform microarray 
hybridizations. The baseline characteristics of the participants are shown in 
Table 1. No significant differences were present between the intervention 
groups, both for the whole group, and the subgroup on which the microarrays 
were performed. To confirm the amount of the various fatty acids the participants 
consumed daily, the fatty acid composition of the capsules was measured (Table 
2). The high dose of EPA/DHA provided 1093 ± 17 mg EPA (mean ± SD) and 847 
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± 23 mg of DHA daily and the low dose of EPA/DHA provided 226 ± 3 mg EPA and 
176 ± 4 mg of DHA daily.
Table 1 Baseline characteristics of array and QPCR subjects.
High EPA/DHA Low EPA/DHA HOSF
QPCR subjects Array subjects QPCR subjects QPCR subjects Array subjects
Subjects (n) 36 23 37 38 25
Gender (M/F) 21/15 15/8 20/17 25/13 15/10
Age (years) 70.3 (67-76) 69.9 (67-76) 70.5 (66-79) 70.9 (66-80) 70.4 (67-77)
Smokers (n) 1 0 4 3 2
Weight (kg) 76.6(60.1-106.7)
78.
 (60.1 – 106.7)
75.3
(47.6-101.8)
79.1
(59.1-108.6)
81.1
(59.1 – 109.5)
Height (m) 1.71 (1.58-1.86) 1.72(1.58 – 1.86) 1.70 (1.53-1.87) 1.73 (1.57-1.87)
1.72
(1.57 – 1.87)
BMI (kg/m2) 26.2(21.12-33.6)
26.5
(21.7 – 33.6) 25.8 (19.9-34.9) 26.5 (20.2-37.2)
27.6
(20.2 – 42.3)
TG (mmol/L) 1.14 (0.4-3.3) 1.02 (0.4-2.0) 1.17 (0.2-3.8) 1.18 (0.4-2.7) 1.20 (0.5-2.7)
FFA (mmol/L) 0.38 (0.12-0.71) 0.35 (0.12-0.59) 0.36 (0.08-0.99) 0.34 (0.06-0.98) 0.36 (0.06-0.98)
EPA (mass%) 1.26 (0.4-4.4) 1.44 (0.6-4.4) 1.43 (0.4-5.0) 1.30-(0.4-8.5) 1.38 (0.4-8.5)
DHA (mass%) 0.62 (0.3-1.1) 0.65 (0.3-1.1) 0.66 (0.2-1.6) 0.64 (0.4-1.3) 0.63 (0.4-1.3)
Table 2 Composition of the capsules (%). SFA, saturated fatty acids; MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
 High EPA/DHA Low EPA/DHA HOSF
HOSF 22.08 10.40 8.46
MUFA 14.73 67.97 80.53
c18:1n-9 Oleic acid 4.66 64.38 79.63
PUFA 53.39 20.23 11.02
c18:2n-6 Linoleic acid 0.74 9.13 10.81
c20:5n-3 EPA 21.40 4.49 0.00
c22:6n-3 DHA 16.44 3.46 0.00
Plasma measurements 
To check compliance of individual intake, plasma fatty acid composition was 
determined in cholesteryl esters at baseline and after 26 weeks (Figure 1A). 
Both EPA and DHA were significantly elevated (p<0.01) in the low and high EPA/
DHA groups compared with baseline. Plasma EPA concentrations showed a mean 
increase of 348% in the high EPA/DHA group and a mean increase of 83% in the 
low EPA/DHA group. Mean plasma DHA concentration increased with 97% and 
31%, respectively. No changes were observed in the group that consumed the 
HOSF capsules. Plasma triglyceride concentrations were significantly decreased 
after 26 weeks in the high EPA/DHA group (p<0.01), and not in the low EPA/DHA 
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or HOSF group (Figure 1B). Plasma free fatty acids (FFA) were also significantly 
decreased after 26 weeks in the high EPA/DHA group (p<0.01), and not in HOSF 
group. The FFA in the low EPA/DHA showed a tendency to decrease, although 
this was not statistically significant (p=0.06) (Figure 1C).
Figure 1 Changes in plasma lipid metabolites after intake of EPA/DHA or HOSF capsules for 26 
weeks compared with baseline in all 111 participants. A) Plasma cholesterylesters EPA and DHA B) 
Plasma triglyceride concentrations C) Plasma total free fatty acid concentrations. Values are mean 
±SEM, * p<0.01 compared with baseline.
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Microarray analysis
Microarray hybridization was performed on PBMC RNA that was collected at 
baseline and after 26 weeks of supplementation from 25 subjects from the high 
EPA/DHA group and 26 subjects from the HOSF group. Two arrays in the high 
EPA/DHA group and one array in the HOSF group did not pass the quality control 
criteria. Changes in gene expression were determined by comparison of the 
microarray results of the samples after 26 weeks of intervention with microarray 
results of the baseline samples, in both intervention groups. From the 17,699 
genes present on the microarray 12,256 genes were defined as expressed in 
PBMCs (Figure 2). Consumption of 1.8 g of EPA/DHA daily for 26 weeks resulted 
in gene expression changes of 1040 genes, whereas consumption of the HOSF 
capsules resulted in changes of 298 genes (Figure 2). Of these genes, 140 genes 
overlapped between the groups, resulting in 900 uniquely changed genes in the 
EPA/DHA group. Except for one gene, the direction of change of the overlapping 
genes was the same in the EPA/DHA and the HOSF group (data not shown). 
Figure 2 Flow chart of gene selection and number of genes changed in the microarray analysis. Q, 
false discovery rate Q value.
Pathway analysis
To determine the role of the genes that changed upon EPA/DHA supplementation 
in pathways, signaling routes or networks, we performed pathway analysis on 
all data. GenMAPP analysis revealed that supplementation with a high dose of 
EPA/DHA for 26 weeks significantly decreased expression of genes involved in 
inflammatory pathways, such as eicosanoid synthesis, interleukin signaling and 
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MAP kinase signaling (Figure 3). In addition, a decrease in gene expression in 
pathways related to atherosclerotic processes, such as cell adhesion, scavenger 
receptor activity and adipogenesis was observed. Other pathways negatively 
regulated by EPA/DHA supplementation were transcription factor binding 
and the cancer signaling pathway EGFR1 NetPath 4. Pathways that were up-
regulated upon EPA/DHA supplementation were cell cycle regulation and RNA 
transcription, processing and binding.
Figure 3 (left page) Ranking of differentially expressed pathways in PBMC after 26 week 
supplementation of high EPA/DHA or HOSF capsules in elderly individuals. Pathway analysis was 
performed with the program GenMAPP. Pathways included had a z-score of at least 1 and had at least 
2 genes changed.
Analyses with Ingenuity pathway analysis (IPA) revealed similar decreases in 
inflammatory signaling routes, such as IL6 and MAP kinase, with additional 
signaling routes such as NF-κB and Toll-like receptor signaling. IPA also showed a 
decrease in PPAR signaling, LXR/RXR activation, glycosaminoglycan degradation 
and hypoxia signaling in the cardiovascular system, which includes hypoxia 
initiation factor 1α (HIF1α) signaling (data not shown). Moreover, Gene Set 
Enrichment Analysis (GSEA) confirmed the decreases found in inflammatory 
signaling pathways, such as eicosanoid metabolism, IL6 and MAP kinase 
signaling. Also oxidative stress, cell adhesion and PPAR signaling were down-
regulated (data not shown). 
Interestingly, pathway analysis of genes changed in the HOSF group also 
showed down-regulation of genes involved in inflammation and cell adhesion (Figure 3). However, the expression of fewer genes was changed upon HOSF 
intake, and consequently, fewer genes were observed in the changed pathways. 
In addition to the genes present in the analyzed pathways, several other genes 
involved in similar processes were down-regulated as well, and are depicted in 
Figure 4. This list shows various inflammatory genes, such as NF-κB target genes, 
oncostatin M (OSM), Ig-like receptors and interleukin receptors, that were down-
regulated in the high EPA/DHA group. Also, gene expression of several plaque 
stability-related metallopeptidases was decreased after 26 weeks of EPA/DHA 
supplementation (Figure 4).
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Process Gene name Description Entrez ID Mean FC EPADHA
EPADHA: 
q-value
MUFA: 
q-value
Inflammation
inflammatory signaling
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1051 -1.11
DUSP1 dual specificity phosphatase 1 1843 -1.15
DUSP2 dual specificity phosphatase 2 1844 -1.50
MKNK1 MAP kinase interacting serine/threonine kinase 1 8569 -1.06
OSM oncostatin M 5008 -1.24
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 3572 -1.20
IL13RA1 interleukin 13 receptor, alpha 1 3597 -1.17
NFIL3 nuclear factor, interleukin 3 regulated 4783 -1.25
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 2114 -1.16
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 1978 -1.12
H3F3B H3 histone, family 3B (H3.3B) 3021 -1.09
LILRB3 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 11025 -1.11
LILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 11027 -1.15
LILRA5 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 353514 -1.32
C5AR1 complement component 5a receptor 1 728 -1.19
FADD Fas (TNFRSF6)-associated via death domain 8772 1.15
NF-kB signaling
IRAK3 interleukin-1 receptor-associated kinase 3 11213 -1.32
IRAK1 interleukin-1 receptor-associated kinase 1 3654 -1.09
MAP3K3 mitogen-activated protein kinase kinase kinase 3 4215 -1.08
GSK3B glycogen synthase kinase 3 beta 2932 -1.14
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 7133 -1.07
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 7128 -1.34
PRKACB protein kinase, cAMP-dependent, catalytic, beta 5567 1.08
PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide 5287 1.08
LTA lymphotoxin alpha (TNF superfamily, member 1) 4049 1.19
eicosanoid synthesis
LTA4H leukotriene A4 hydrolase 4048 -1.06
ALOX5 arachidonate 5-lipoxygenase 240 -1.12
GPX3* glutathione peroxidase 3 (plasma) 2878 -1.26
TBXAS1 thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) 6916 -1.12
CBR3 carbonyl reductase 3 874 1.15
Toll like receptor signaling
TLR8 toll-like receptor 8 51311 -1.11
TLR5 toll-like receptor 5 7100 -1.18
CD14 CD14 molecule 929 -1.12
Cell adhesion
integrin mediated cell adhesion
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 3684 -1.08
ITGA7 integrin, alpha 7 3679 -1.06
GRB2 growth factor receptor-bound protein 2 2885 -1.07
GAB2 GRB2-associated binding protein 2 9846 -1.20
VAV2 vav 2 guanine nucleotide exchange factor 7410 -1.07
VAV3 vav 3 guanine nucleotide exchange factor 10451 -1.09
PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 5058 -1.13
CD2 CD2 molecule 914 1.11
chemokine signaling
CXCL16* chemokine (C-X-C motif) ligand 16 58191 -1.17
CXCR4 chemokine (C-X-C motif) receptor 4 7852 -1.28
CCR3 chemokine (C-C motif) receptor 3 1232 -1.15
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) 23236 -1.19
PLCL2 phospholipase C-like 2 23228 -1.07
CXCL5 chemokine (C-X-C motif) ligand 5 6374 1.18
CX3CR1 chemokine (C-X3-C motif) receptor 1 1524 1.14
CCR5 chemokine (C-C motif) receptor 5 1234 1.24
PF4 platelet factor 4 (chemokine (C-X-C motif) ligand 4) 5196 1.12
PF4V1 platelet factor 4 variant 1 5197 1.21
CXCR3 chemokine (C-X-C motif) receptor 3 2833 1.20
Macrophage differentiation/foam cell formation
scavenger receptor activation
CXCL16* chemokine (C-X-C motif) ligand 16 58191 -1.17
CD36* CD36 molecule (thrombospondin receptor) 948 -1.13
LDLR* low density lipoprotein receptor (familial hypercholesterolemia) 3949 -1.18
CD163 CD163 molecule 9332 -1.12
SCARB2 scavenger receptor class B, member 2 950 -1.09
adipogenesis
ADFP* adipose differentiation-related protein 123 -1.01
SCD stearoyl-CoA desaturase (delta-9-desaturase) 6319 -1.12
NCOA1 nuclear receptor coactivator 1 8648 -1.12
RXRA retinoid X receptor, alpha 6256 -1.12
NRIP1 nuclear receptor interacting protein 1 8204 -1.28
IRS2 insulin receptor substrate 2 8660 -1.30
GADD45B growth arrest and DNA-damage-inducible, beta 4616 -1.12
DDIT3 DNA-damage-inducible transcript 3 1649 -1.13
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 4282 1.07
plaque stability
MMP25 matrix metallopeptidase 25 64386 -1.07
MMP15 matrix metallopeptidase 15 (membrane-inserted) 4324 -1.07
TIMP2 TIMP metallopeptidase inhibitor 2 7077 -1.12
ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 8754 -1.12
ADAMTSL4 ADAMTS-like 4 54507 -1.15
ADAM8 ADAM metallopeptidase domain 8 101 -1.05
Oxidative stress
ROS protection
SOD2 superoxide dismutase 2, mitochondrial 6648 -1.14
GPX3* glutathione peroxidase 3 (plasma) 2878 -1.26
MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 4094 -1.16
JUNB jun B proto-oncogene 3726 -1.16
JUND jun D proto-oncogene 3727 -1.06
FTH1 ferritin, heavy polypeptide 1 2495 -1.15
BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 571 -1.15
HIF signaling
HIF1A hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 3091 -1.10
VEGFA vascular endothelial growth factor A 7422 -1.19
CREB5 cAMP responsive element binding protein 5 9586 -1.29
PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 5728 -1.14
UBE2E2 ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) 7325 -1.01
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 4792 -1.17
UBE2D1 ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) 7321 -1.11
nitrix oxide production
NOS3 nitric oxide synthase 3 (endothelial cell) 4846 1.10
NOSIP nitric oxide synthase interacting protein 51070 1.07
Process Gene name Description Entrez ID Mean FC EPADHA
EPADHA: 
q-value
MUFA: 
q-value
PPAR signaling
ACVR2A activin A receptor, type IIA 92 -1.01
ADIPOR2 adiponectin receptor 2 79602 -1.06
CD36* CD36 molecule (thrombospondin receptor) 948 -1.13
LDLR* low density lipoprotein receptor (familial hypercholesterolemia) 3949 -1.18
ADFP* adipose differentiation-related protein 123 -1.01
Cell cycle
CDK2 cyclin-dependent kinase 2 1017 1.07
TP53 tumor protein p53 (Li-Fraumeni syndrome) 7157 1.07
CDK4 cyclin-dependent kinase 4 1019 1.08
PCNA proliferating cell nuclear antigen 5111 1.09
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 3265 1.10
LCK lymphocyte-specific protein tyrosine kinase 3932 1.11
MCM6 minichromosome maintenance complex component 6 4175 1.11
CCND2 cyclin D2 894 1.14
RPA2 replication protein A2, 32kDa 6118 1.06
RPA3 replication protein A3, 14kDa 6119 1.08
down-regulated
not significant
p val <0.1 and >0.05
p val <0.05 and >0.01
p val < 0.01
up-regulated
not significant
p val <0.1 and >0.05
p val <0.05 and >0.01
p val < 0.01
Figure 4 Genes changed after EPA/DHA supplementation reflected in 
various functional groups that were overrepresented by the pathway 
analyses software programs GenMAPP, IPA and GSEA, supplemented 
with changed genes also related to these processes. Asterisks indicate 
that the genes appear in multiple functional groups. FC, fold change.
Additionally, we examined the expression changes of previously described PPARα 
target genes in PBMCs89 and observed that 14 out of these 106 PPAR response 
element-containing PPARα target genes were down-regulated, and two were up-
regulated (Table 3). 
Table 3 Previously described PPARα target genes in PBMCs89 found to be changed upon high EPA/DHA 
supplementation. FC, fold change; FDR Q, false discovery rate Q value.
Gene Description Gene name Entrez ID Mean FC FDR Q
Heparin-binding EGF-like growth factor HBEGF 1839 -1.40 0.021
Pyruvate dehydrogenase kinase isozyme 4 PDK4 5166 -1.25 0.027
Zinc finger E-box-binding homeobox 2 ZEB2 9839 -1.21 0.004
Vascular endothelial growth factor A VEGFA 7422 -1.19 0.024
Small inducible cytokine B16 precursor CXCL16 58191 -1.17 0.010
Transcription regulator protein BACH1 BACH1 571 -1.15 0.003
Microphthalmia-associated transcr. factor MITF 4286 -1.15 0.021
Myeloid-assoc. differentiation marker MYADM 91663 -1.14 0.003
Platelet glycoprotein 4 CD36 948 -1.13 0.049
MARVEL domain containing 1 MARVELD 83742 -1.12 0.027
TNF receptor superfamily member 8 TNFRSF8 943 -1.11 0.045
Dihydropyrimidinase-related protein 2 DPYSL2 1808 -1.10 0.026
Adipose differentiation-related protein ADFP 123 -1.10 0.031
Suppressor of tumorigenicity protein 14 ST14 6768 -1.09 0.037
Uncharacterized protein C15orf17 C15orf17 57184 1.11 0.043
Protein Chibby CBY1 25776 1.11 0.036
To determine whether a low dose of 0.4 g EPA/DHA daily can induce similar gene 
expression changes as a high dose of 1.8 g EPA/DHA daily, a selection of six genes 
out of several changed pathways were analyzed with Q-PCR in the whole study 
population of 111 individuals (Figure 5). QPCR of CD36, PDK4, LTA4H, ADFP, CD14 
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and HIF1α revealed that consumption of 0.4 g EPA/DHA daily for 26 weeks also 
resulted in a down-regulation in expression of these genes and that the effects 
were intermediate between the effect of the 1.8 g EPA/DHA group and the HOSF 
group. These data also confirm the microarray results, as reflected by the same 
direction of gene expression changes. 
 
0 | Chapter 4
Figure 5 (left page) Q-PCR results of a selection of genes changed upon high EPA/DHA 
supplementation for the high EPA/DHA, low EPA/DHA and HOSF intervention groups. CD36, CD36 
antigen; PDK4, pyruvate dehydragonase kinase 4; LTA4H, leukotriene A4 hydrolase; ADFP, adipose 
differentiation related protein; CD14, CD14 antigen; HIF1a, hypoxia induced factor 1 alpha. Values 
are mean ±SEM. ** p<0.01 and * p<0.05 compared with baseline.
Discussion
In this study we assessed changes in PBMC gene expression profiles after fish 
oil supplementation and a control in a 26-week double-blind and randomized 
intervention trial in an elderly population. Supplementation of 1.8 g of EPA/
DHA daily, the equivalent of the consumption of ten portions of fatty fish weekly, 
results in anti- inflammatory- and anti-atherogenic-like PBMC gene expression 
profiles. In addition, supplementation with 0.4 g of EPA/DHA daily, representing 
two portions of fatty fish weekly, resulted in similar gene expression changes, but 
with a lower magnitude.
The effects of fish oil on health have been extensively studied. However, the 
impact of fish oil supplementation on whole genome gene expression profiles in 
PBMC has not been examined. To our knowledge, only one study examined the 
effect of fish oil supplementation on human leukocyte gene expression profiles95. 
However, in this study a macroarray containing only 588 genes, was examined 
in an RNA pool of eight volunteers and no control group was included. The 
anti-inflammatory-like gene expression profile observed in the present study 
is mainly characterized by decreased gene expression of inflammatory genes, 
including several NF-κB target genes, pro-inflammatory cytokines, chemokines 
and eicosanoid synthesis. The above described study also observed a decrease 
in expression of some cytokine, chemokine receptor and stress response genes. 
In addition, several other intervention studies with varying doses of n-3 fatty 
acids such as α-linolenic acid (ALA) or EPA/DHA/fish oil, observed a decrease 
in plasma inflammatory markers such as CRP, E-selectin and TNFα96-98 or a 
reduction in cytokine formation after ex vivo stimulation in mononuclear cells99, 100. 
The decrease in eicosanoid formation we found was characterized by a down-
regulation in the gene expression of enzymes involved in eicosanoid synthesis, 
such as LTA4H and ALOX-5. It is known that n-3 PUFA supplementation can result 
in a decrease in pro-inflammatory arachidonic acid derived eicosanoids28. For 
example, various studies show that supplementation of fish oil or DHA for 4 to 
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17 weeks resulted in a decrease in the ex vivo stimulation-induced production 
of eicosanoids, such as prostaglandin E2, thromboxane B2, leukotriene B4 and 
leukotriene E4 (LTE4) in inflammatory cells of healthy volunteers28. In addition, 
intake of n-3 fatty acids for 6 weeks in 14 human volunteers reduced urinary 
excretion of LTE4 (101). Moreover, a 3-week n-3 enriched diet intervention 
study in mice suppressed the generation of both leukotrienes and prostaglandins 
during acute inflammation102. Hence, our observations on PBMC gene expression 
nicely reflect n-3 PUFA-induced effects on plasma and urinary inflammatory 
markers and ex vivo stimulated inflammatory responses.
The group of subjects that consumed the HOSF capsules showed a similar, albeit 
less pronounced effect on some of the inflammatory pathways. The overlapping 
genes were almost all changed in the same direction, suggesting that some of the 
effects on inflammation, although clearly less apparent, are comparable with the 
EPA/DHA intervention. Beneficial effects of MUFAs on inflammation have been 
reported, but only limited data is available103.
The anti-atherogenic gene expression profile that we observed in this study 
after EPA/DHA intake is characterized by a reduced expression of genes that 
play a role in several processes known to be involved in atherosclerotic plaque 
formation. The PBMC subpopulations exist of monocytes/macrophages, and T- 
and B-lymphocytes, which can play a role in adhesion, infiltration and subsequent 
foam cell formation during atherogenic development104. In our study we found an 
EPA/DHA induced decrease in integrin-mediated cell adhesion, characterized by 
down-regulation of genes encoding proteins such as integrin αM, a monocyte cell 
adhesion molecule105, and growth factor receptor-bound protein 2. An n-3 PUFA-
induced decrease in expression of monocyte/macrophage adhesion molecules 
has previously been reported, but only in animal and in vitro studies106, 107. Because 
leukocyte adhesion molecules promote binding of monocytes and T cells to the 
endothelium104, the observed EPA/DHA-induced reduction in gene expression 
might lead to decreased rolling and adhesion of mononuclear leukocytes. 
Besides an EPA/DHA induced decrease in cell adhesion, we also observed 
down-regulation in expression of several chemokine signaling genes, such as 
chemokine receptor CXCR4, which mediates migration of resting leukocytes108. 
However, we observed both up- and down-regulation of several adhesion 
molecules and chemokines related to these processes. Moreover, the increases 
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found in chemokines such as platelet factor 4 (PF4), and its receptor, CXCR3 are 
associated with increased risk of atherosclerosis109, but on the other hand can 
inhibit leukocyte chemotaxis110, and angiogenesis111. Additionally, an increase 
in the chemokine receptor CCR5 was found, which is known to have a higher 
expression in foam cells and activated T cells in mouse and human atheromas112, 
but which is also known to clear chemokines from the site of activation113.
Our study also revealed that EPA/DHA supplementation for half a year reduces 
scavenger receptor activity, as characterized by a lower expression of genes 
encoding CD36 and the LDL receptor. Moreover, we observed a decreased in 
adipogenesis, portrayed by a decrease in expression of genes involved in lipid 
accumulation, such as adipose differentiation-related protein (ADFP). Scavenger 
receptors, such as CD36 and LDLR, are involved in the uptake of particles such 
as oxidized low density lipoproteins (oxLDL). It has been shown that n-3 PUFA 
incubation in monocytes in vitro can reduce scavenger receptor mRNA and protein 
expression114. After uptake, the oxLDL can accumulate in intracellular droplets, 
which requires the action of lipid droplet proteins, such as ADFP115. Incubation of 
macrophages with PUFA-enriched chylomicron remnant-like particles resulted 
in a reduced lipid accumulation in these cells116. Similarly, studies in rats showed 
that EPA feeding inhibits cholesterol ester accumulation in macrophages in 
a dose-dependent manner117. The reduction in gene expression of scavenger 
receptors and ADFP upon EPA/DHA supplementation that we observe in human 
PBMCs are in line with these in vitro data and might imply that the monocytes 
present within the PBMCs are less prone to differentiate into foam cells after 26 
weeks of EPA/DHA supplementation. 
Besides the processes discussed above, we also observed changes in genes 
related to plaque stability, a process that normally occurs after infiltration and 
foam cell formation. Expression of genes of matrix metalloproteinases (MMPs) 
and disintegrin metalloproteinases (ADAMs), endopeptidases that can degrade 
the extracellular matrix, was down-regulated upon EPA/DHA intake. These genes 
are known to destabilize atherosclerotic plaques and thus can result in plaque 
rupture118. Also, hypoxia inducible factor 1α (HIF1α) and its main target gene 
vascular endothelial growth factor (VEGF) were down-regulated119. Both genes 
are known to regulate atherosclerotic plaque angiogenesis, which destabilizes 
and progresses the lesion. Plaque stability has been found to be increased after 
n-3 PUFA supplementation120.
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We also found various markers for oxidative stress, such as superoxide dismutase 
2, glutathione peroxidase 3 and ferritin, down-regulated after EPA/DHA intake. 
Oxidative stress is involved in the initiation and progression of atherosclerosis121 
and the observed reduction in anti-oxidants in this study may imply a decrease 
in oxidative stress in the leukocytes after intake of n-3 PUFAs. PUFAs have been 
shown to moderate oxidative stress, as measured in urine or blood in several121, 122 
but not in all studies123. Because highly unsaturated fatty acids are more prone to 
oxidation, concern exists that high intake of n-3 PUFA might lead to an increased 
susceptibility to oxidative stress. However, it has been suggested that in 
individuals consuming n-3 PUFAs, fatty acids are initially more readily oxidized, 
but that the total oxidation is lower123. Long term intake of EPA/DHA as assessed 
in this study might therefore result in reduced oxidative stress. 
High EPA/DHA intake in our study also increased expression of nitric oxide 
synthase 3 (NOS3/eNOS), which plays a role in protection of the vessel wall from 
atherosclerosis124. Increased expression of eNOS in murine macrophages and 
in vitro in human vascular wall cells after supplementation or incubation with 
EPA/DHA has been shown before125-127. Importantly, the studies described, all 
illustrate short term in vitro experiments or animal studies, while we observed 
our effects in humans after 26 weeks of n-3 PUFA intake. 
In this study, PBMC gene expression changes nicely reflect anti-inflammatory and 
anti-atherogenic changes and we may speculate that EPA/DHA supplementation 
will improve the pre-atherosclerotic condition in elderly people. Another 
interesting point to discuss is whether the changes in gene transcription profiles 
are due to a direct effect of EPA/DHA in mononuclear cells or whether the changes 
reflect the response of PBMCs to EPA/DHA induced systemic adaptations. This is 
nicely illustrated by the unexpected finding of down-regulation of PPARα target 
genes after EPA/DHA supplementation. Based on mice and in vitro studies, in 
which a more pronounced expression of PPAR target genes upon EPA and DHA 
intake than upon saturated or monounsaturated fatty acid intake was shown90, 
we expected an increase in PPARα target genes upon EPA/DHA supplementation 
instead of the observed decreases. A possible explanation for these unexpected 
findings may lie in systemic adaptations by effects of EPA/DHA on gut or liver, 
resulting in reduced plasma FFA and TG concentration. The observed down-
regulation of PPAR target genes, but also of other genes such as scavenger 
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receptors, might have been caused by these reduced plasma FFA and TG 
concentrations. The down-regulation of these genes might be due to systemic 
action of EPA/DHA as a consequence of long term adaptation, rather than by a 
direct effect in the PBMCs. Hence, PBMC gene expression profiles could also be 
viewed as a reflection of the physiological state of subjects, as we have shown 
previously67. The potential of gene expression profiles as biomarkers has already 
been recognized in the pathological field8, 86, but this study demonstrates that 
also nutritional interventions can significantly induce changes in PBMC gene 
expression profiles. 
 
One of the remarks that should be made concerning the nutritional intervention 
is that the high dose of EPA/DHA in this study is comparable to a relatively high 
consumption of ten portions of fatty fish weekly. However, Q-PCR results show 
that a lower dose, representing the intake of two portions of fatty fish weekly, 
resulted in similar, but lower, gene expression changes. This suggests that lower 
amounts of fish intake may have similar effects on PBMC gene expression profiles, 
especially when taken for a longer period. The HOSF group showed an even 
smaller, but still detectable modulatory effect on expression of inflammatory 
genes. The HOSF capsules contained approximately four grams of oleic acid, 
which is an addition of about 16% MUFA for woman and 13% MUFA for men over 
65 years old to the normal Dutch, western diet128. The small changes seen in the 
HOSF group might have been the result of this increased intake of MUFA. 
Our study population consisted of elderly individuals, which likely express 
a slightly more pro-inflammatory and pro-atherosclerotic gene expression 
profile, since it has been shown that ageing is associated with chronic, low grade 
increased inflammatory activity129. This makes the studied population suitable to 
detect nutritional effects on these transcriptional profiles. The observed effects 
of EPA/DHA on PBMC gene expression profiles can therefore not directly be 
translated to younger populations. Interestingly, a recent study in obese men 
showed that weight loss reduced expression of inflammatory genes in PBMCs87. 
In the present study we find similar anti-inflammatory changes in PBMC gene 
expression of lean subjects, merely by supplementation with 1.8 g/d, and even 
0.4 g/d of EPA/DHA. This emphasizes the potential of PBMC gene expression 
profiling to determine the effects of nutrition on human health status.
In conclusion, this study reveals that intake of the n-3 PUFAs EPA and DHA for 26 
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weeks alters gene expression profiles of PBMCs in the direction of a more anti-
inflammatory and anti-atherogenic-like profile. Moreover, this nutrigenomics 
study demonstrates that PBMC profiling can not only reflect pathological 
conditions or the physiological state, but can also reflect metabolic changes due 
to long term nutritional adaptations. 
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Abstract
Background
Dietary polyunsaturated fatty acids (PUFAs) have been suggested to have a variety 
of beneficial effects, of which the effects on inflammation and cardiovascular 
diseases are most generally accepted. Immune cells play an important role in 
these processes, but the mechanisms of action of PUFAs on these cells are still 
not completely understood. It is known that PUFAs can elicit effects on gene 
expression. Since most individuals are in a postprandial state for the main part 
of the day, knowledge about direct effects of fatty acids on immune cells is highly 
valuable.
Design
In a single blind cross over study, 21 healthy male volunteers consumed shakes 
enriched in PUFAs, monounsaturated (MUFA) or saturated fatty acids (SFA) in 
random order. Before and at several time points after intake of the shakes blood 
was drawn and PBMCs were isolated to use for gene expression analysis. Whole 
genome gene expression profiles were examined before and 6 hours after intake 
of the PUFA and SFA shakes. Additionally, ex vivo incubations of human PBMC 
with different fatty acids were performed.
Results
Whole genome expression analysis showed distinct differences between PUFA 
and SFA consumption in PBMCs. Consumption of the PUFA shake resulted in 
a decrease expression of genes in LXR signaling, while SFA intake showed an 
increase in these same genes. PUFA intake also demonstrated an increase in 
genes related to cellular stress responses. MUFA intake had an intermediate 
effect on several genes. Additional ex vivo experiments revealed a direct effect of 
DHA on PBMC gene expression. 
Conclusions
PBMC microarray analysis allows to detect subtle differences in the effects of 
different types of dietary fatty acids on whole genome gene expression profiles.
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Introduction
Dietary polyunsaturated fatty acids (PUFAs) are suggested to have a variety of 
beneficial effects, of which the effects on inflammation (28) and cardiovascular 
diseases130 are the most generally accepted. Immune cells play an important role 
in inflammation and the development of cardiovascular disease. However, the 
mechanisms of action of PUFAs on the functions of immune cells are still not 
completely understood131. It is known that PUFAs can mediate their effects through 
changes in gene expression, mainly regulated via activation of transcription 
factors, such as peroxisome proliferator-activated receptors (PPARs) and LXR59, 132. 
Whole genome transcriptional profiling of immune cells would elucidate all 
processes that PUFAs regulate on gene expression level. Most studies that 
examined the effect of PUFAs on human immune cells have been performed in 
long term intervention trials133, and were related to the immunological function 
of these cells. However, whole genome expression studies have not been carried 
out. Only one study showed that intake of PUFA-rich fish oil for 2 months changed 
expression of several genes related to inflammation in leukocytes95, but only a 
selected set of 588 genes were examined. Furthermore, measures in long term 
studies are mostly performed in fasted samples. However, most individuals are 
in a postprandial state for the greater part of every 24 hour period, and therefore 
knowledge about postprandial effects of different fatty acid types on these 
cells are highly valuable. It is unknown whether different fatty acids can elicit 
differential postprandial effects on gene expression of immune cells of human 
individuals, and what these effect will encompass. Therefore, we examined the 
postprandial effects of consumption of a shake containing 70 energy% of fat in 
the form of PUFA (65% of total fat), SFA (70% of total fat) or monounsaturated 
fatty acids (MUFA, 80% of total fat) on gene expression changes in PBMCs of 21 
healthy men in a cross-over design. Whole genome microarray analyses were 
performed before and 6 hours after PUFA- and SFA-enriched shake consumption. 
To explore the response kinetics, Q-PCR analysis were performed before and at 5 
time points after intake of all shakes. 
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Subjects and Methods
Recruitment of subjects
Twenty-one healthy male Caucasian volunteers, between 19 and 27 years of 
age were recruited from the Wageningen student population. Exclusion criteria 
were a body mass index (BMI) < 18 or > 27 kg/m2, urine protein or glucose 
concentrations outside normal ranges or fasting blood glucose outside the 
normal range. Other exclusion criteria were: tobacco smoking, taking regular 
prescribed medication, received inoculations within 2 months of starting the 
study or planned to during the study, donated or intended to donate blood 
within 8 weeks of the first and last study samples, diagnosed with any long-term 
medical condition (e.g. diabetes, hemophilia, cardiovascular disease, anemia, 
gastrointestinal disease), experiencing symptoms of allergy, or vegetarian. 
Subjects were informed about the design and purpose of the study and provided 
full informed written consent.
Study design 
At a screening visit, urine and fasting venous blood samples were taken 
to determine glucose concentrations in both urine and blood, and protein 
concentrations in urine. 
In a cross-over design, the twenty-one male subjects randomly consumed three 
shakes enriched with polyunsaturated (PUFA), monounsaturated (MUFA) 
or saturated fatty acids (SFA) on three different days, with at least one week 
between each study day. Before each study day, subjects received identical meals 
containing less than 10 gram of fat, which they had to consume before 8 pm the 
previous evening. On the morning of each study day the subjects came to the 
University in fasted condition and before the start of the study a canula was place 
in their forearm. At the start of the study 6 ml of blood was drawn into EDTA 
tubes for plasma isolation and 24 ml into BD Vacutainer Cell Preparation Tubes 
with sodium citrate (BD, Breda, The Netherlands) for PBMC isolation. Directly 
after the first blood sampling the subjects were given a shake, which they had 
to consume within 10 minutes. Subsequently, every 2 hours blood was drawn, 
until 8 hours after intake of the shake. During a study day, the subjects were 
not allowed to eat or drink anything except water, which they were advised to 
drink regularly (approximately 150 ml each hour). After 8 hours, the volunteers 
received a meal. Subjects were asked to keep record of their physical condition 
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during the complete study period, which lasted from January 14th, 2008 till March 
7th, 2008. The study protocol was approved by the Medical Ethical Committee of 
Wageningen University.
Shake constituents
The shakes contained 350 ml of low-fat yoghurt, 100 ml of skimmed milk, 7,5 gram 
sugar and 55 gram of the test fat. Vitamin E (165 mg) was added as antioxidant. 
The test fats were 65% polyunsaturated fatty acids, of which approximately 
40% docosahexaenoic acid (DHA) (PUFA shake, Marinol D-40, Lipid Nutrition, 
Wormerveer, the Netherlands); 80% monounsaturated fatty acids, predominantly 
oleic acid (MUFA shake, high oleic acid sunflower oil, Aldoc BV, Schiedam, the 
Netherlands), or 70% saturated fatty acids (SFA shake, butter). Composition of 
the shakes was calculated using the computer package KOMEET134. This program 
is based on the database of the Dutch Nutrient Databank135. Fat percentages were 
measured by gas–liquid chromatography (GLC)136. 
Blood glucose and plasma free fatty acids and triglycerides
Blood glucose concentrations were determined with Accu-Chek Compact blood 
glucose meters (Roche Applied Science). Immediately after blood drawing, blood 
in the EDTA tubes was centrifuged (750 x g, 4 °C, 10 min), and plasma was stored 
at -80˚ C. Plasma free fatty acids and triglycerides were measured by gas–liquid 
chromatography (GLC). 
PBMC isolation and flow cytometry analysis
Immediately after blood collection, PBMCs were isolated using the BD Vacutainer 
Cell Preparation Tubes according to the manufacturer’s manual. Cells were 
counted at baseline and 6 hours after intake of the shakes, and tested for viability 
by trypan blue exclusion. Flow cytometry analysis was performed on 1.5 x 106 
cells using a FACS Canto II flow cytometer (BD Biosciences). Data was analyzed 
using BD FACSDiva software (BD Biosciences).
Total RNA isolation
PBMC RNA was isolated from all PBMC samples using the Qiagen RNeasy Micro 
kit (Qiagen, Venlo, the Netherlands). RNA yield was quantified on a Nanodrop 
ND 1000 spectrophotometer (Nanodrop technologies, Wilmington, Delaware 
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USA) and integrity was measured on an Agilent 2100 Bioanalyzer with RNA 6000 
Nano chips (Agilent Technologies, South Queensferry, UK). 
Microarray processing
PBMC samples from baseline and 6 hours after intake of the PUFA and the SFA 
shakes were used for microarray analysis, resulting in a total of 84 arrays. Total 
RNA from PBMCs from all subjects was labeled using a one-cycle cDNA labeling 
kit (MessageAmpTM II-Biotin Enhanced Kit, Ambion, Inc.) and hybridized to 
human whole genome NuGO GeneChip arrays encoding 17,699 genes, designed 
by the European Nutrigenomics Organisation (NuGO) and manufactured by 
Affymetrix (Affymetrix Inc, Santa Clara, CA). Sample labeling, hybridization 
to chips and image scanning was performed according to the manufacturer’s 
GeneChip Expression Analysis Technical Manual (Affymetrix).
Microarray analysis
All microarrays fulfilled our quality control criteria. Microarrays were analyzed 
using the reorganized oligonucleotide probes as described by Dai et al (2005)68. 
Dai et al. combined all individual probes for a gene, enabling the possibility to 
detect the overall transcription activity of a gene, based on the latest genome 
and transcriptome information, instead of the Affymetrix probe set annotation. 
Expression values were calculated using the Robust Multichip Average (RMA) 
method. RMA signal value estimates are based on a robust average of background 
corrected perfect match intensities and normalization was performed using 
quantile normalization41, 42. Only genes with normalized signals higher then 
20 on at least 10 arrays were defined as ‘expressed’ and selected for further 
analysis. Genes were defined as ‘changed’ when comparison of the normalized 
signal intensities showed an FDR Q-value93 lower than 0.05 in a two-tailed paired 
t test with Bayesian correction (Limma)69. 
Pathway analysis
Pathway analysis was performed using Ingenuity Pathway Analysis 5.5 (Ingenuity 
Systems). Array data has been submitted to the Gene Expression Omnibus, 
accession number GSE13466.
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cDNA synthesis and real time PCR
RNA from all subjects and shakes was reverse transcribed with the use of a cDNA 
synthesis kit (Promega, Leiden, the Netherlands). Standard quantitative real-time 
polymerase chain reaction (Q-PCR) was performed with the use of Platinum Taq 
DNA polymerase and SYBR Green on an iCycler PCR machine (Bio-Rad Laboratories 
BV) and duplicated at least twice. Primer sequences used in the PCRs were chosen 
based on the sequences available in PRIMERBANK (http://pga.mgh.harvard.
edu/ primerbank/index.html). Q-PCR data were normalized by measuring cycle 
threshold ratios between candidate genes and a housekeeping gene, human 
ribosomal protein LP0, which was shown to be consistent within PBMCs45.
PBMC incubation studies
Blood from 4 healthy Caucasian male donors, aged between 26 and 42 yr, was 
obtained from the blood bank (Sanquin, Nijmegen) and PBMCs were isolated 
directly after arrival using Ficol-paque Plus density gradient centrifugation 
(Amersham Biosciences, Roosendaal, the Netherlands). PBMCs were incubated 
in RPMI1640 medium with 2 mmol/L L-glutamine, 10% fetal bovine serum and 
antibiotics (penicillin and streptomycin) in the presence of 5% CO
2
 at 37°C. at 1.0 
x 106 cells per ml, for 12 hours. Bovine serum albumin was added to bind fatty 
acids and the following fatty acids were tested; palmitic acid (C16.0, 200 μmol/
L), oleic acid (C18.1, 500 μmol/L) and docosahexaenoic acid (C22.6, 10 μmol/
L). Concentrations were based on physiologically normal levels of the different 
fatty acid types found in plasma of volunteers in a previous study67. These were 
compared to KOH solution, in which the fatty acids were dissolved, as control. All 
donors gave full written informed consent.
Statistical methods
In this cross-over study, each subject consumed the three shakes and is used 
as his own reference. Data are given as mean ± SEM, n=21. Incremental shake 
responses (means over 21 determinations) are expressed as variations in 
concentration or relative gene expression value over baseline (fasting baseline 
values being zero). The 0 to 8 hour incremental area under the curve (AUC) was 
calculated by the trapezoidal method. The significance of the difference among 
the experimental shakes, the 0 to 8 hour time points for a given shake and the 
difference between shake AUCs were assessed using a repeated measures ANOVA 
PBMC gene expression reflects fatty acid intake | 85
and a Least Significance Difference (LSD) post hoc test. A two tailed paired t-
test was used to determine significant differences in percentages of blood cells 
in PBMCs between baseline and 6 hours after intake of the shakes. Statistical 
significance was accepted at p<0.05. All calculations were performed by using 
the SPSS-software package 15.0.1 (Chicago, Illinois).
Results
Subject characteristics
Twenty-one healthy men were included in the study, who returned to the 
University on three separate study days to consume a shake enriched with 
polyunsaturated (PUFA), monounsaturated (MUFA) or saturated fatty acids 
(SFA). Microarray analyses were performed for the PUFA and SFA enriched 
shakes. Subject characteristics, as measured during the screening visit, are shown 
in Table 1. The shakes contained 2824 kJ of energy and consisted of 18.4 grams 
protein, 34 gram of carbohydrates and 55 gram of fat. The fatty acid composition 
was determined by GLC and is shown in Table 2. No differences were observed 
in blood cell subpopulations between the study days and no changes were found 
after intake of the PUFA or SFA shakes, although the latter was tested in five 
individuals, only (data not shown). 
Table 1 Subject characteristics of the men participating in the study
 Mean (n=21) Range
Age (y) 21.5 18 - 27
Height (m) 1.84 1.76 - 1.96
Weight (kg) 74.4 62 - 87
BMI (kg/m2) 22.1 18.1 - 26.3
Fasting glucose (mmol/L) 4.8 4.3 - 5.5
Table 2 Percentages of fatty acids as measured by gas–liquid chromatography136
PUFA SFA MUFA 
Total fat (En%) 71.5 71.5 71.5
    Saturated (% of total fat) 18.51 70.73 7.63
    Monounsaturated (% of total fat) 15.04 25.46 84.62
    Polyunsaturated (% of total fat) 65.77 2.39 7.75
        n-6 polyunsaturated (% of total fat) 6.77 1.35 7.75
        n-3 polyunsaturated (% of total fat) 59.00 1.04 0.00
            Docosahexaenoic acid (% of total fat) 48.54 0.00 0.00
            Eicosapentaenoic acid (% of total fat) 7.24 0.00 0.00
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Plasma FFA and TG, and blood glucose concentrations changed in time
Intake of all shakes resulted in a similar decrease in blood glucose and increase 
in total FFA in time. All shakes increase plasma TG concentrations, but the PUFA 
shake resulted in significantly higher TG concentration at t=6 and at t=8 hours 
compared to the SFA shake at the same time points. The MUFA shake appeared 
to have an intermediate effect. No significant differences in total response, as 
measured by incremental area under the curves (AUC), of triglycerides, glucose 
and FFA responses were observed between the shakes (Figure 1).
Figure 1 Effects of consumption of three shakes, providing polyunsaturated (PUFA), 
monounsaturated (MUFA) or saturated fatty acids (SFA), on plasma triglycerides (A), plasma total 
free fatty acids (B), and blood glucose (C) in healthy men. Values are means ± SEM, n = 21. The 
incremental areas under the curve (AUC) are shown in inserts. Different letters indicate a difference (p <0.05) between shakes at a given time. For a given test shake, a filled symbol indicates that the 
corresponding value differs (p <0.05) from baseline (0 h) value. 
Microarray analysis
Microarray hybridization was performed on PBMC RNA that was collected at 
baseline and 6 hours after consumption of the PUFA shake and the SFA shake of 
all 21 subjects. All arrays passed the quality criteria. Changes in gene expression 
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were determined by comparison of the microarray results of the samples of t=6 
hours with t=0 hours within all individuals in both intervention groups. From the 
17,699 genes present on the microarray, 13,365 genes were defined as expressed in 
PBMCs (Figure 2). Consumption of the PUFA shake resulted in expression changes 
of 437 genes, whereas consumption of the SFA shake resulted in expression changes 
of 297 genes (Figure 2). Of these genes, 146 genes overlapped between the groups, 
of which all except two were changed in the same direction. These two genes, ABCG1 
and SREBF1, were down-regulated after PUFA shake intake, and up-regulated after 
SFA shake intake. Beside determining which genes were significantly changed 
within the shakes, we also elucidated whether gene expression was significantly 
changed between the shakes. A strict FDR Q-value below 0.05 revealed changes in 
expression between shakes for 3 genes, ABCG1, SREBF1 and ABCA1. 
Figure 2 Gene selection procedure and criteria FDR Q, false discovery rate Q value.
Gene expression changes
To elucidate the role of the various genes which expression was changed after 
consumption of the shakes, pathway analysis was performed. This revealed 
that those genes were involved in processes related to Liver X receptor (LXR) 
signaling, oxidative stress, inflammation, carbohydrate metabolism, and a variety 
of other processes (Figure 3). 
Figure 3 (right page) Pathways changed in PBMC gene expression profiles after consumption of 
the PUFA or SFA shakes, grouped by processes. Pathway analysis was performed with the program 
Ingenuity Pathway Analysis.
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Figure 4 shows a heat map of the genes involved in LXR signaling, of which 
expression was changed upon intake of at least one of the shakes. In most 
individuals SFA shake consumption resulted in an increase in expression of 
genes involved in LXR signaling such as LXR (NR1H3), ABCG1, SREBF1 and ABCA1, 
whereas PUFA shake consumption resulted in a down-regulation of the same 
genes. PUFA shake consumption resulted in gene expression changes indicating 
both an increase and a decrease in oxidative stress (Figure 3). Glutathione 
metabolism genes (e.g. GSTK1, GSTP1, MGST3) were responsible for the down-
regulation of this pathway and genes involved in activation of inflammatory and 
cellular stress pathways were responsible for the up-regulation of this pathway 
after PUFA shake consumption. SFA shake consumption did not show a strong 
effect in stress responses on pathway level (Figure 3). However, a variety of pro-
inflammatory and stress-related genes were also up-regulated after SFA shake 
intake, including MAP3K1, CD40 and ICAM1 (data not shown). In addition, we 
examined the changes in expression of previously described PPARα target genes 
in human PBMCs89. We found that out of the total of 106 PPAR response element-
containing PPARα target genes, 6 genes were changed after PUFA shake intake 
and 5 genes after SFA shake intake, of which 4 were overlapping between shakes, 
including PDK4 (data not shown).
GENE NAME PUFA SHAKE INTAKE SFA SHAKE INTAKE
CYP27A1
ABCA1
NR1H3
ABCG1
SREBF1
SCD
LDLR
Figure 4 Heat map of genes changed after consumption of the PUFA or SFA shakes, within the 
process LXR signaling, with a FDR Q value below 0.05, in all 21 individuals. Red indicates up-
regulation, green indicates down-regulation, black indicates no change. 
To elucidate the response in gene expression in time and upon the MUFA shake, 
quantitative real time-PCR (Q-PCR) was performed for all time points after 
intake of the three shakes on a selection of genes. Genes were selected out of the 
pathways changed upon shake intake and included PDK4, LXR, ABCA1, SREBF1, 
cJUN and GSTP1. These genes showed that consumption of the shakes enriched 
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with PUFA, MUFA and SFA resulted in different gene expression responses in time, 
and also confirmed the microarray results, as reflected by the same direction of 
gene expression changes six hours after PUFA and SFA shake intake (Figure 5). 
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Figure 4 shows a heat map of the genes involved in LXR signaling, of which 
expression was changed upon intake of at least one of the shakes. In most 
individuals SFA shake consumption resulted in an increase in expression of 
genes involved in LXR signaling such as LXR (NR1H3), ABCG1, SREBF1 and ABCA1, 
whereas PUFA shake consumption resulted in a down-regulation of the same 
genes. PUFA shake consumption resulted in gene expression changes indicating 
both an increase and a decrease in oxidative stress (Figure 3). Glutathione 
metabolism genes (e.g. GSTK1, GSTP1, MGST3) were responsible for the down-
regulation of this pathway and genes involved in activation of inflammatory and 
cellular stress pathways were responsible for the up-regulation of this pathway 
after PUFA shake consumption. SFA shake consumption did not show a strong 
effect in stress responses on pathway level (Figure 3). However, a variety of pro-
inflammatory and stress-related genes were also up-regulated after SFA shake 
intake, including MAP3K1, CD40 and ICAM1 (data not shown). In addition, we 
examined the changes in expression of previously described PPARα target genes 
in human PBMCs89. We found that out of the total of 106 PPAR response element-
containing PPARα target genes, 6 genes were changed after PUFA shake intake 
and 5 genes after SFA shake intake, of which 4 were overlapping between shakes, 
including PDK4 (data not shown).
GENE NAME PUFA SHAKE INTAKE SFA SHAKE INTAKE
CYP27A1
ABCA1
NR1H3
ABCG1
SREBF1
SCD
LDLR
Figure 4 Heat map of genes changed after consumption of the PUFA or SFA shakes, within the 
process LXR signaling, with a FDR Q value below 0.05, in all 21 individuals. Red indicates up-
regulation, green indicates down-regulation, black indicates no change. 
To elucidate the response in gene expression in time and upon the MUFA shake, 
quantitative real time-PCR (Q-PCR) was performed for all time points after 
intake of the three shakes on a selection of genes. Genes were selected out of the 
pathways changed upon shake intake and included PDK4, LXR, ABCA1, SREBF1, 
cJUN and GSTP1. These genes showed that consumption of the shakes enriched 
Figure 5 (previous page) Effects of consumption of three shakes, providing polyunsaturated 
(PUFA), monounsaturated (MUFA) or saturated fatty acids (SFA), on gene expression of several 
genes that were selected because they were changed 6 hours after intake of the PUFA and/or the 
SFA shake as assessed with microarray analysis. PDK4, pyruvate dehydrogenase kinase 4; LXR, liver 
X receptor; ABCA1, ATP-binding cassette A1; SREBF1, sterol regulatory element binding protein-
1; GSTP1, glutathione S transferase P1; JUN, jun oncogen. Values are means ± SEM, n = 21. The 
incremental areas under the curve (AUC) are shown in inserts. Different letters indicate a difference (p <0.05) between shakes at a given time. For a given test shake, a filled symbol indicates that the 
corresponding value differs (p <0.05) from baseline (0 h) value.
Ex vivo incubation experiments
To explore whether the observed in vivo effects on gene expression changes 
were direct effects of the increased different FFA concentrations in plasma, we 
performed ex vivo incubation of PBMCs with different fatty acids representing 
the main fatty acid types in the three shakes, i.e. palmitic acid as SFA, oleic acid 
as MUFA and docosahexaenoic acid as PUFA. Q-PCR of ABCA1 in all four subjects 
revealed increases after SFA, and decreases after PUFA incubation. In 3 out of 
4 subjects ABCA1 expression was increased after MUFA incubations. SREBF1 
showed a similar decrease after PUFA incubation, and increases in 3 out of 4 
subject after SFA and MUFA incubations. These changes were comparable to 
changes in gene expression observed after consumption of the different shakes. (Figure 6).
92 | Chapter 
Figure 6 Effects of incubation of PBMCs from donors with three different fatty acids, which represent 
the main fatty acid types in the experimental shakes, on expression of several genes changed 
after shake intake. Values are means ± SEM, n=4. C16:0, palmitic acid; C18:1, oleic acid; C22:6, 
docosahexaenoic acid. ABCA1, ATP-binding cassette A1; SREBF1, sterol regulatory element binding 
protein- 1;
Discussion
This study describes the results of a single blind, cross-over trial, and demonstrates 
that consumption of high fat shakes varying in their fatty acid composition, 
results in postprandial fatty acid-specific gene expression profile changes in 
PBMCs. The difference in the gene expression profiles were characterized by 
differential effects on LXR signaling, glutathione metabolism, oxidative stress 
and inflammation. 
For genes involved in LXR-signaling opposite effects of both shakes were 
found. The PUFA enriched shake decreased expression of genes involved in 
LXR signaling, whereas consumption of the SFA enriched shake resulted in an 
increased expression of the same genes. Most of these genes are target genes of 
LXR, and include ABCG1, ABCA1 and SREBF1. Kinetics of the changes in expression 
of SREBF1 and ABCA1 in the hours following shake consumption revealed that 
differences between the two shakes were already present respectively 2 and 4 
hours after consumption of the shakes and lasted up to 8 hours. This indicates a 
rapid response upon intake of fatty acids that disappears within several hours. 
The LXR target genes ABCA1 and ABCG1 play a major role in reverse cholesterol 
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transport in macrophages137 and several in vitro studies have shown that PUFAs 
can decrease expression of these genes in macrophages138, 139. Our data is in 
line with these findings, because PUFA shake intake showed that expression of 
ABCA1 and ABCG1 was down-regulated and our ex vivo experiments showed that 
PBMC incubation with human DHA decreased ABCA1 expression. However, the 
effect of dietary PUFA or SFA consumption on PBMC gene expression in humans 
has never been studied before and therefore the observed fatty acid-dependent 
response of ABCA1 and ABCG1 expression are completely new in that respect. 
Another target gene of LXR, SREBF1 was also down-regulated upon PUFA intake 
and encodes a transcription factor involved in fatty acid synthesis and cholesterol 
metabolism140. Also for this transcription factor, no human in vivo experiments 
have been performed before, but in vitro studies have shown that PUFAs inhibit 
expression of SREBF1 in hepatocytes141 and embryonic kidney cells142, which 
we also demonstrated in our ex vivo PBMC experiments after DHA incubation. 
Besides down-regulation of SREBF1 upon PUFA shake intake, its target gene, SCD, 
was also down-regulated after PUFA shake consumption, whereas no change 
in regulation was found after SFA shake consumption. SCD is the rate-limiting 
enzyme in the cellular synthesis of monounsaturated fatty acids and expression 
of SCD was shown to be decreased by PUFAs through regulation of SREBF1 in 
animal and in vitro studies143, which is clearly in accordance with our in vivo 
study findings. Yoshikawa et al. showed that PUFAs inhibit binding of LXR to LXR 
response elements in the promoter of LXR target genes such as SREBF1142. This 
repression of LXR target genes might also have happened in PBMCs of our in vivo 
study after consumption of the PUFA enriched shakes with a possible inhibition 
of cholesterol efflux and subsequent reverse cholesterol transport. Conversely, 
the increase in LXR target gene expression after SFA shake consumption might 
result in an increased cholesterol efflux out of the cells. However, it is hard to 
conclude whether SFA directly induce LXR activation, or whether cholesterol 
or its metabolites serve as ligands for LXR in these cells144. Since the SFA shake 
was made with butter fat, it contained more cholesterol than the PUFA shake. 
Moreover, we did not observe a clear increase in LXR target gene expression after 
ex vivo PBMC incubation with SFA. Also interesting in this respect is the observed 
decrease in expression of the low-density lipoprotein receptor (LDLR), which 
mediates uptake of LDL cholesterol in cells, after SFA shake consumption. LDLR 
is known to be an LXR target gene that is up-regulated after LXR activation145, but 
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is down-regulated in our study, while other LXR target genes are up-regulated. 
On the other hand, rises in cellular cholesterol levels have shown to reduce 
transcription of LDLR146, which might be the cause of our observed down-
regulation in LDLR in human PBMCs after consumption of the SFA shake.
Another difference observed between consumption of both fatty acids was the 
response in cellular stress. PUFA consumption induced both an increased and 
decreased expression of genes involved in cellular stress response as illustrated 
by the up- and down-regulation of genes involved in NRF-2 mediated metabolism, 
whereas no effects were observed after SFA consumption. The down-regulated 
genes were involved in glutathione coupled metabolism, and mainly encoded 
glutathione S-transferases (GSTs), whereas the up-regulated genes were related 
to inflammation and cellular stress, such as cJUN, a component of activator 
protein 1, a transcription factor that regulates gene expression in response to 
a broad variety of stress stimuli. This bidirectional regulation of cellular stress 
points toward an initial triggering of the cells, and may work as a protective 
response mechanism of the cell.
The changed cellular stress response upon PUFA consumption shows that the 
use of a relatively high dose of DHA in the shakes is a suitable challenge strategy 
to induce cellular system perturbation, with the ultimate goal to reveal the 
resilience of the cells. Contrary, the PBMCs seemed to be capable of dealing 
with the high dose of the more common consumed saturated fatty acids with 
less difficulty, resulting in lower cellular stress responses. In addition, unlike 
the results of our postprandial study, long term high PUFA intake is capable of 
reducing stress in several studies147, 148. However, where long term interventions 
will provide information about the nutritional effects on whole body homeostasis, 
postprandial fat intake will provide information about the actual metabolic 
capacity of cells to deal with this increased lipid flow. For instance, prolonged 
intake of lower doses of DHA will probably increase the capacity of metabolic 
organs, such as intestine and liver, to more efficiently handle these potential 
stressors. This may result in an overall increased capability of the body to handle 
these lipids, and consequently lower stress response. 
Within this study only one shake was consumed, but as we are in the postprandial 
state the largest part of the day, this raises the question what would happen with 
gene expression profiles, if several high fat challenges are given during the course 
of the day.
A interesting point to address is the low number of PPARα target genes which 
expression was changed after intake of the various shakes. Only a few PPARα 
target genes, including PDK4, ADFP and SLC25A20 were found to be increased, 
and no differences were observed between the different shakes. PUFAs are 
known to be better ligands for PPARs then SFA and we therefore expected that 
PUFA shake intake would result in higher PPAR target gene expression then 
consumption of the SFA shake. In a previous study we observed that many more 
PPARα target genes were increased after 24 hour fasting than after shake intake 
in the current study, but we also found that endogenous derived plasma total 
FFA were much higher increased during fasting than after shake consumption. 
It seems that postprandial gene expression changes in human PBMCs are not 
regulated through PPARα or that other regulatory processes are more important 
in these cells. 
This study is the first study that demonstrated that PBMC gene expression 
profiles can not only be used to differentiate between health and disease, as has 
been elucidated by previous whole genome gene expression studies8, 10, but are 
also able to reflect postprandial changes that differ in type of fatty acid, only. It 
is known that the transcription of the cell will not change if the cell can handle 
the alteration in the environment. Therefore, challenge strategies combined with 
gene expression profiling of PBMC, as utilized within this study, can elucidated 
the capacity of cell systems to deal with stressors, such as the studied PUFAs, in 
a comprehensive manner. For future studies, it would be of interest to study if 
PBMC gene expression profiles reflect metabolic capacity upon fatty acid intake 
in subjects with diet-related disorders such as diabetes or metabolic syndrome, 
of whom the metabolic capacity is already retarded, and whether the responses 
would differ from healthy individuals. 
In summary, our study shows that PBMCs are sensitive enough to show fatty 
acid-specific gene expression profiles after consumption of different fatty acids. 
Moreover, gene expression profiles of these cells can provide detailed information 
about cellular stressor handling capacity upon induction of a challenge. This 
makes these cells highly interesting for future utilization in the elucidation of the 
influences of nutrition on human homeostasis.
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General discussion
General discussion
The objective of this thesis was to elucidate the influence of nutrients such 
as fatty acids on whole genome gene expression profiles of peripheral blood 
mononuclear cells, which are circulating immune cells in the body. Our initial 
study was aimed as proof of principle in which we showed a marked change 
in PBMC gene expression profiles upon fasting, which elevates free fatty acid 
(FFA) concentrations in the blood, and demonstrated that the gene expression 
profiles of these cell can reflect this physiological condition in human individuals (chapter 2). In subsequent ex vivo PBMC studies we investigated the role of 
PPARα activation, of which several target genes were increased during fasting. 
We observed that gene expression changes after PPARα activation were regulated 
in a person specific manner (Chapter 3). This study indicated that it is possible 
to study PPARα in a comprehensive way in human PBMCs. After establishment of 
the role of PPARα in PBMCs, two nutritional intervention studies were performed 
which revealed that long term supplementation with polyunsaturated fatty acids 
(PUFAs) leads to changes in PBMCs that are characterized by an anti-inflammatory 
and anti-atherogenic gene expression profile (Chapter 4). The postprandial 
challenge study resulted in an change in cellular stress-related gene expression 
markers after consumption of PUFAs (chapter 5). Additionally, exact opposite 
postprandial effects of PUFA and SFA consumption on expression of LXR target 
genes were observed, demonstrating a reduced expression of these genes after 
PUFA intake and an increased expression after SFA intake.
Altogether these studies demonstrate that PBMC gene expression profiling 
is applicable in human dietary intervention studies. In addition, potential 
mechanisms underlying changes in gene expression after consumption of 
different fatty acids were revealed. 
There are a few points to address when comparing data of all studies described 
in this thesis. The fact that the fatty acid-sensing nuclear receptor PPARα is 
expressed in human PBMCs was one of the arguments why PBMCs would be 
interesting cells to study fatty acid-dependent gene expression. Upon fasting, 
when FFA rise, several target genes of PPARα were increased. However, when we 
examined data of the nutritional intervention studies, expression of only a few 
PPARα target genes was changed. Since PUFAs are known to be better ligands 
for PPARs, we also expected that PUFA intake would result in increased PPARα 
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target gene expression compared with other fatty acids. Interestingly, for the long 
term PUFA supplementation study we did observe differences between the two 
fatty acid groups. However, instead of the expected increase, we observed that 
long term PUFA supplementation resulted in a down-regulation of PPARα target 
genes, while no such effect was observed for the MUFA group. In the postprandial 
study, PPARα target gene expression was increased, but no differences between 
the different fatty acid groups was observed. One of the likely reasons for the low 
number and direction of PPARα target gene changes in the nutritional intervention 
studies when compared with the fasting study, may be the difference in total 
plasma FFAs. After fasting, total FFA are extremely increased, with a consequent 
increased expression of a high number of PPARα target genes, whereas plasma 
total FFA are far less increased postprandially, with a consequent much lower 
number of PPARα target genes with an increased expression. Moreover, after 
long term PUFA intake, plasma total FFA are even decreased with a consequent 
decreased expression in PPARα target genes. 
Besides the difference in PPARα target gene expression between the long and 
postprandial intervention, opposite effects were also observed on inflammatory 
gene expression profiles, which showed anti-inflammatory characteristics after 
long term PUFA intake, and more stress related responses, postprandially. 
We hypothesize that during long term PUFA supplementation, when PUFAs are 
consumed regularly and in a low dose, the body could gradually adapt to the 
constant challenge of PUFA molecules that serve as excellent transcriptional 
activators through nuclear receptors such as PPARs. Moreover, this will directly 
or indirectly have effects on other transcription factors that are involved in lipid 
handling and inflammation, such as SREBPs, LXRs, FXRs, HNF4 or even NF-κB149, 
which will lead to significant enhancement of metabolic functions of target organs 
such as intestine, liver, adipose tissue, endothelial system or heart. In the long 
run, this might contribute to the apparent positive effects found in the long term 
study. In contrast, saturated fatty acids (in particular C 16:0 and C18:0) that are 
more abundantly present in the normal western diet are less potent activators 
of the above mentioned transcription factors, or have even opposite effects, 
that may contribute to lower metabolic capacity and slightly pro-inflammatory 
conditions150, 151. Therefore, long term exposure to chronically high levels of 
saturated fat, as in a western style diet, characterized by low variability of food 
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patterns, would not sufficiently trigger the adaptability of organs, mediated in 
part by members of the nutrient sensing-nuclear receptor super-family, such as 
PPARs. This may in the end result in a less healthy phenotype of the individual. 
Hence, where long term fatty acid intake results in PBMC gene expression 
profiles reflecting more systemic adaptations of the body, postprandial profiles 
likely reflects more direct effects of the fatty acids on the cellular system. This 
acute effect may be explained by the fact that cellular gene expression will 
only change when the cellular system is not capable of handling the nutritional 
challenge. In this case, cellular regulators, such as transcription factors, will be 
activated and regulate gene expression to deal with the environmental changes. 
Conversely, when gene expression is not changed, apparently the cell is fully 
capable of handling the challenge. Hence, application of nutritional challenges 
such as described in chapter 5, will provide measures for cellular metabolic 
capacity.
Besides the studies described in these thesis, other studies have been performed 
that explored the feasibility of human nutrigenomics using circulating blood 
cells. Van Erk et al152 examined the effects of a high-carbohydrate and a high-
protein breakfast on gene expression of blood cells. However, paracetamol was 
added to the breakfasts to measure gastric emptying. Paracetamol is known to 
have profound effects on gene expression of peripheral blood cells153 and might 
therefore have influenced the found results. In addition, in their study whole 
blood RNA isolation was used, which has been shown to increase noise and 
reduce responsiveness in gene expression profiles compared to the isolation of 
RNA from separated PBMCs154. Another study showed that a relatively strong 
intervention of 8-week low calorie diet decreased expression of oxidative 
stress and inflammation related genes in PBMCs87. To our knowledge, only one 
study examined the effect of fish oil supplementation on human leukocyte gene 
expression95. However, only 588 genes using a macroarray, instead of the more 
comprehensive microarrays used in our studies containing at least 2/3 of the 
human genome (17.699 genes), were examined in a pool of eight volunteers. 
We are convinced that the studies that are described in this thesis contribute 
substantially to the field of human nutrigenomics and that the current knowledge 
on PBMC gene expression profiles is highly promising for future applications. 
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Gene expression profiles of these cells have clearly shown their potential and can 
bring a significant contribution to nutritional science in human subjects.
Future perspectives of human PBMC-based nutrigenomics 
applications
Within all studies described in this thesis, PBMCs were used as starting point 
for all analyzes. PBMCs, however, consist of different subpopulations and within 
the observed gene expression profiles characteristics were found that have 
been described for specific subpopulation. Each cell population within PBMCs 
has its own function and will therefore express cell type-specific genes17, 155. 
Isolation of the various subpopulations from blood is feasible, but still requires 
substantial amounts of blood and long isolation procedures, which introduce the 
risk of activating the cells, ensuing changes in transcription profile. Nevertheless, 
elucidation of fatty acid-specific effects on those subpopulation may facilitate the 
identification of molecular mechanisms of action of these fatty acids. 
The research in this thesis focused on fatty acids or a synthetic counterpart, only. 
Future efforts must be taken to show whether interventions with other nutrients 
also results in gene expression profiles changes in PBMCs. However, it can be 
expected that other macronutrients, such as carbohydrates and proteins, or 
micronutrients, such as vitamins, which are also known to bind to and activate 
transcription factors, will alter gene expression profiles. In addition, effects of 
whole food based dietary intervention, in which different transcription activating 
nutrients are combined in food products, should be examined. Nevertheless, 
these studies are only the start in the elucidation of the effect on fatty acids on 
whole genome transcriptional profiling. 
One of the interesting aspects described within this thesis is the individual 
response that was observed after an ex vivo challenge test (Chapter 3). These 
individual differences in PBMC gene expression profile response are often seen 
as a hindrance in the search for common responses or biomarkers. Conversely, 
these specific responses can be seen as a virtue, specifying each individual 
gene expression profile, enabling them to be used as personalized response 
fingerprints. Identification of the origin of these individual response profiles 
might bring us a step closer to realization of subject specific measurements with 
the ultimate goal to provide individuals with personalized dietary advise.
In addition, the differences in metabolic response upon the in vivo challenge test 
with different fatty acids might be useful to measure flexibility of the human 
system. Future research can further evaluate the power of this test for usages as 
a dietary consumption test or as a measure for health state. For instance, people 
with a western type diet, consuming hardly any fish, may respond different 
on a challenge of DHA than people consuming generally considered healthier 
diets that contain higher amounts of fish. In addition, people with diabetes may 
respond differently to a DHA challenge test than healthy subjects that should 
possess higher metabolic flexibility. 
The ultimate goal is to identify individuals that are not sick yet, but are in the 
process of developing a diseases. This provides the ability to intervene with diet 
before the onset of the disease, in order to prevent instead of cure. Identification 
of such a “non-health” state requires also excellent phenotyping of the subject, 
that can be performed with advanced imaging techniques, such as magnetic 
resonance imaging (MRI), and functional tests, such as vascular function 
measures. In addition, in order to form a comprehensive set of information, 
besides transcriptomics, other genomic techniques, such as metabolomics and 
proteomics, should be utilized.
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Samenvatting
Achtergrond informatie
Nutrigenomics is de studie van de invloed van voeding op de expressie van genen. 
Het doel van nutrigenomics is om deze veranderde expressie van vele genen 
te vertalen naar veranderingen in fysiologische processen die de gezondheid 
beïnvloeden.
De mens heeft ruim 20.000 genen en de informatie van deze genen ligt 
opgeslagen op het DNA, dat in de kern van onze cellen te vinden is. Genen zijn 
de informatiedragers die ervoor zorgen dat er eiwitten worden geproduceerd 
in verschillende soorten cellen. Wanneer dat vereist is zal een gen afgelezen 
worden van het DNA en wordt er een kopie van dat gen gemaakt (transcriptie), 
in de vorm van messenger (boodschapper) RNA (mRNA). Deze kopieën worden 
vervolgens vertaald in eiwitten die een bepaalde functie in de cel of in het lichaam 
zullen gaan vervullen. Hoewel alle cellen in het menselijk lichaam hetzelfde DNA 
hebben, zullen niet alle genen in alle cellen altijd even actief zijn. Zo zullen er 
in cellen met verschillende functies ook verschillende genen afgeschreven 
worden. Bovendien kunnen er ook binnen dezelfde celsoort verschillende genen 
geactiveerd worden, afhankelijk van de omgevingssituatie en de processen in de 
cel. Genen kunnen dus “aan” of “uit” staan. Wanneer een gen “aan” staat en er dus 
mRNA wordt gemaakt, zeggen we dat een gen “tot expressie komt”. De expressie 
van een gen kun je dus bepalen door de hoeveelheid van het bijbehorende mRNA 
vast te stellen.
Met behulp van hedendaagse technieken zijn we in staat om de expressie 
(activiteit) van bijna alle genen van de mens tegelijkertijd te bepalen. Dit doen we 
door gebruik te maken van zogenaamde microarrays. Deze microarrays zijn kleine 
glasplaatjes van 1 cm2 waarop fragmenten van duizenden genen zijn gefixeerd. 
Wanneer we het mRNA uit cellen isoleren en deze op dit plaatje aanbrengen, 
zal dit mRNA vastplakken aan de bijbehorende fragmenten. Hierdoor weten we 
welk en hoeveel mRNA aanwezig is in onze cellen, en dus welke en in welke mate 
genen tot expressie komen in deze cellen. Op deze manier is het mogelijk om 
de genexpressie van cellen te vergelijken onder verschillende omstandigheden, 
bijvoorbeeld voor en na een maaltijd. 
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Van verschillende voedingsstoffen, waaronder vetzuren, is bekend dat ze de 
expressie van genen kunnen beïnvloeden. Vetzuren kunnen ingedeeld worden 
aan de hand van de mate van verzadiging en de lengte van de vetzuurketens. De 
meest voorkomende vetzuren in onze voeding zijn de enkelvoudig onverzadigde 
(in het Engels: monounsaturated fatty acids; MUFAs) en de verzadigde 
vetzuren (saturated fatty acids; SFAs). Meervoudig onverzadigde vetzuren 
(polyunsaturated fatty acids; PUFAs) komen in kleinere hoeveelheden voor, maar 
zijn relatief belangrijk, omdat het menselijk lichaam niet in staat is alle PUFAs uit 
andere vetzuren te maken. Omdat deze wel nodig zijn in het lichaam moeten we 
deze PUFAs binnenkrijgen via onze voeding. 
Vetzuren beïnvloeden de expressie van genen door te binden aan bepaalde 
eiwitten in de cel. Deze eiwitten heten transcriptiefactoren, omdat ze de 
transcriptie (het maken van een kopie) van genen reguleren. Vetzuren binden 
aan de transcriptiefactor die PPAR wordt genoemd. Door deze binding wordt 
PPAR geactiveerd en worden genen afgeschreven die bijvoorbeeld betrokken zijn 
bij de regulatie van vetverbranding in cellen. Via de binding met PPAR reguleren 
vetzuren dus het proces van verwijdering van vetzuren in de cellen.
Omdat voor het bestuderen van de genexpressie cellen nodig zijn, is het moeilijk 
om dit soort onderzoek in gezonde mensen uit te voeren. Het is namelijk niet 
makkelijk om lever- of darmcellen te verkrijgen uit gezonde mensen. Bloedcellen 
zijn echter relatief gemakkelijk te verkrijgen via het afnemen van bloed. Bovendien 
is al gebleken dat witte bloedcellen, en dan met name de perifere bloedcellen 
lymfocyten en monocyten (zogenaamde PBMCs), gebruikt kunnen worden om 
verschillen in genexpressie aan te tonen tussen zieke mensen en gezonde mensen. 
Aangezien PBMCs een belangrijke rol spelen in het afweersysteem, heeft ziekte 
een vrij sterk effect op de genexpressie van deze cellen. Het was echter onduidelijk 
of de veel minder sterke effecten van voedingsstoffen op de genexpressie ook 
te detecteren zijn in PBMCs. De aanwezigheid van PPAR, de transcriptiefactor 
voor vetzuren, in PBMCs was een doorslaggevende reden om ons te richten op de 
effecten van vetzuren op de genexpressie van humane PBMCs. 
Onderzoeksvraagstelling
Met het onderzoek dat beschreven staat in dit proefschrift wilden we bestuderen 
of veranderingen van type en hoeveelheid vetzuren in de voeding terug te zien 
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zijn in de genexpressie profielen van humane PBMCs. Vervolgens wilden we 
onderzoeken of we uit deze profielen konden afleiden welke invloed vetzuren 
hebben op de verschillende processen in PBMCs. 
Resultaten 
In het eerste onderzoek hebben we gekeken naar de effecten van twee dagen vasten 
op de genexpressie profielen in PBMCs van vier jonge mannen. Tijdens vasten 
nemen de vetzuurconcentraties in het bloed sterk toe. Daarom is deze situatie 
ideaal om te kijken of de genexpressie profielen van PBMCs ook veranderen. In 
dit onderzoek zagen we inderdaad veranderingen in genexpressie profielen van 
PBMCs na de vastenperiode. Veel genen waarvan de expressie veranderde bleken 
betrokken te zijn bij de vetverbranding. Daarnaast bleek dat veel genen waarvan 
de expressie veranderde, genen waren waarvan bekend was dat ze door PPARα, 
een subtype van PPAR, gereguleerd worden. 
Daarom hebben we in een tweede onderzoek bestudeerd hoe groot de rol van 
deze transcriptiefactor PPARα was in PBMCs. Dit hebben we gedaan door PBMCs 
te isoleren uit het bloed van 6 bloeddonoren en ze samen met Wy14,643, een 
op vetzuren lijkend stofje, in een petrischaaltje te kweken en vervolgens de 
veranderingen in genexpressie te bepalen. Het voordeel van Wy14,643 ten 
opzichte van echte vetzuren is dat Wy14,642 alleen PPARα activeert, en geen 
andere PPAR subsoorten. Hierdoor weten we zeker dat de veranderingen die we 
vinden in de genexpressie van PBMCs na incubatie met Wy14,643, toegekend 
kunnen worden aan de activiteit van PPARα. In dit onderzoek vonden we dat 
PPARα de expressie van ongeveer 10% van de genen in PBMCs reguleert. Ook 
vonden we dat de 6 bloeddonoren na activatie van PPARα persoon-specifieke 
veranderingen in genexpressie profiel lieten zien. Na vergelijking van de 
resultaten van deze studie met de analyses van de eerste studie ontdekten we 
dat PPARα ook tijdens vasten een aanzienlijke rol speelt. 
In de twee hierop volgende studies hebben we onderzocht of korte en lange 
termijn veranderingen in inname van verschillende vetzuren terug te zien zijn in 
PBMC genexpressie profielen. In de lange termijn studie hebben oudere mensen 
6 maanden lang capsules geslikt met daarin ofwel visolie, dat meervoudig 
onverzadigde vetzuren (PUFAs) bevat, ofwel een controle olie met enkelvoudig 
onverzadigde vetzuren (MUFAs). We vergeleken de genexpressie profiel 
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veranderingen van PBMCs na 6 maanden visolie suppletie met de genexpressie 
profiel veranderingen na 6 maanden controle olie. Uit de studie bleek dat na het 
innemen van visolie met PUFAs de genexpressie een deels anti-stress profiel liet 
zien in PBMCs, terwijl je daar veel minder van zag na inname van de controle olie 
met MUFAs. 
In de korte termijn studie hebben 21 jonge mannen drie verschillende 
milkshakes gedronken die alleen verschilden in het type vetzuur. Een milkshake 
bevatte PUFAs, MUFAs of verzadigde vetzuren (SFAs). We hebben genexpressie 
profiel veranderingen in de PMBCs van deze mannen, zes uur na inname van de 
milkshakes, vergeleken tussen de PUFA en de SFA milkshake. Verder hebben we 
voor enkele genen gekeken naar de genexpressie veranderingen in de tijd, tot 8 
uur na de inname van de drie verschillende milkshakes. Uit de studie bleek dat 
inname van de PUFA-milkshake andere veranderingen in genexpressie profielen 
in PBMCs liet zien dan inname van de SFA-milkshake. Vooral cholesterol-
regulerende genen kwamen meer tot expressie na de SFA-milkshake dan na de 
PUFA-milkshake. Metabole stress-gerelateerde genen kwamen juist meer tot 
expressie na de PUFA-milkshake, terwijl dat na de SFA-milkshake veel minder 
het geval was. 
Wanneer we het lange termijn onderzoek vergeleken met het korte termijn 
onderzoek, dan valt op dat direct na inname van PUFAs meer stressgerelateerde 
genen tot expressie lijken te komen, maar dat na lange termijn inname van PUFAs 
juist het omgekeerd lijkt te gebeuren. Wij denken dat dit komt omdat PUFAs de 
cellen kunnen stimuleren, waardoor stressgerelateerde genen aangezet worden, 
maar dat dit er op de lange termijn voor zorgt dat de cellen beter met PUFAs 
om kunnen gaan. Met andere woorden, de capaciteit van de cellen om stress-
inducerende factoren te verwerken neemt toe.
Conclusies
PBMC genexpressie profielen reflecteren veranderingen in vetzuurinname in de 
mens en zijn in staat om vetzuur-afhankelijke genexpressie patroon veranderingen 
te laten zien na inname van verschillende type vetzuren. Daarnaast kunnen we 
uit deze profielen processen afleiden die zouden kunnen veranderen in cellen 
naar aanleiding van de aanpassingen in de voeding.
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Dankwoord 
En dan nu, het belangrijkste onderdeel van dit boekje. Ik mag mijn naam dan 
voorop schrijven, maar het was zeker niet zover gekomen zonder een hele hoop 
anderen. In dit laatste stukje tekst wil ik dan ook graag mijn dank uitspreken 
voor al hetgeen zij voor mij hebben betekend... 
Allereerst natuurlijk diegenen die dit alles mogelijk hebben gemaakt, en die mij 
in de laatste vier jaar vaak de weg hebben gewezen.
Michael, al begreep ik niet altijd direct welke kant je opging met je ideeën, door 
de vele discussies en de vrijheid die je me hebt gegeven, heb ik enorm veel ge-
leerd de afgelopen vier jaar. Je werd gedurende die periode steeds enthousiaster 
over de resultaten en de mogelijkheden van het humane onderzoek en dat was 
een enorm goede motivatie voor mij. Hartelijk dank voor alles.
Lydia, je bent niet alleen een geweldig leuke ‘baas’, maar in de loop der jaren 
ook een voorbeeld als wetenschapper voor mij geworden. Jouw kritische, directe 
mening heeft mij meer dan eens wakker geschud, je uitgebreide kennis en inzich-
ten hebben mij veel geleerd over de manier waarop wetenschap bedreven moet 
worden en ik heb ontzettend genoten van al onze uitgebreide discussies. Ik hoop 
dat we deze nog vaker zullen hebben, en aangezien ik nu slechts een steenworp 
verderop werk, zal dat vast en zeker het geval zijn! 
Naast deze directe begeleiding waren er altijd anderen in de buurt waar ik te-
recht kon voor een vraag of met een probleem. Guido, bedankt voor je soms ste-
vige commentaar, en al die momenten waarop je weer een array-analyse aan me 
uitlegde. Je was nooit te beroerd om me ergens mee te helpen, van het uitleggen 
van een computer programma, tot het meehelpen legen van mijn snoepla. San-
der, je had vaak sterke kritische noten bij mijn werk, wat me erg motiveerde, en 
was altijd in voor wat ontspanning op de gang. Al moet je wel wat beter leren 
gooien…(ik kom niet terug om weer een bal van het dak te halen J). Wilma, 
je bent in veel dingen compleet het tegenovergestelde van mij (gestructureerd, 
georganiseerd, precies, duidelijk, etc), maar juist je kritische houding en opmer-
kingen hebben mij vaak enorm geholpen. Mijn dank daarvoor is groot! 
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Er zijn een hoop mensen die in hetzelfde (AIO-)schuitje zitten (of zaten) als ik 
zat, en ik wil hen allemaal even bedanken:
Rinke, als kamergenoot was het makkelijk om dingen snel aan je te vragen, en 
je had dan ook een grote hoeveelheid kennis waar ik vaak gebruik van heb ge-
maakt. Daarnaast hebben we ook aardig wat gelachen en ik zal nooit vergeten 
dat je zo vriendelijk was om de dief op onze kamer mijn portemonnee te wijzen 
en hoe ik bijna opgepakt ben omdat ik me uitgaf voor jou!! Heleen, ik kon altijd 
bij jou de kamer binnenlopen en een gezellig gesprek beginnen, even ontspannen 
en geintjes maken. We hebben veel lol gehad tijdens het klimmen, al kwam dat er 
de laatste tijd niet veel meer van. Bedankt voor het verduidelijken van vele zaken 
die een rol spelen in het AIO-leven, vooral tijdens mijn beginperiode. Meike, een 
goed gesprek en relativering kon ik altijd bij je vinden, hoe druk (en chaotisch) 
je ook bezig was. Jouw kennis was ook altijd zeer nuttig en gewoon even kletsen 
over iets anders was altijd fijn. Jeroen, we delen de liefde voor games en je tips 
en uitleen-games hebben me veel plezier en ontspanning gebracht. Linda, I al-
ways admired your calm and relaxed way of dealing with everything, and I really 
enjoyed your sense of humor on several occasions. Anand, thanks for teaching 
me about bayesian stuff and all those difficult computer things. You are by far 
the most friendly man I have ever met. Your great sense of humor and easy going 
mentality always make me feel good and I really enjoyed all the squash-games we 
played and probably will play in the future. Fokko, we deelden de gedrevenheid 
om het lekker laat te maken (al ben ik nooit door een raam naar buiten gegaan, 
ik had gewoon de code voor het alarm J). David, thanks for choosing me as your 
paranimph, and for the fun time we had organizing the PhD tour and actually 
being in the UK and Ireland. We had a great time, and I will never forget what we, 
together with Anand, found on top of the closet in that hostel! Saskia, je bent niet 
lang na mij begonnen en hoewel je wat tegenslagen te verwerken hebt gehad, 
geloof ik best dat het allemaal goed komt. Ik vond het altijd heel leuk om geintjes 
met (en over J) je te maken (het Limburgs leent zich er nu eenmaal uitstekend 
voor) en ik heb ook erg genoten van de squash-avonden. Laten we die voortzet-
ten! Laeticia, besides the enormous amount of fun we had in our room, we also 
had some good discussions and you learned me a lot about this weird protein 
you love so much, FIAF (what did the letters stand for again?!). ...vous êtes com-
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plètement taré! And off course, also thanks to your mum, who was so much fun 
during our trip to Marrakesh, even though we could not understand each other 
to well. (ce n’est pas jolie!). David, jouw rustige en goedlachse uitstraling waren 
een constante factor in de groep, en ook al hebben we weinig met elkaar te ma-
ken gehad, jouw vriendelijk lach was altijd welkom. Natasha, greek woman, you 
never stopped talking and was always hungry, two really funny qualities, which 
always made me laugh. You are a really positive person, and I am very happy to 
know you. Susan en Diewertje, jullie hebben altijd een lach op je gezicht en stra-
len van de positieve energie. Daarnaast doen jullie ontzettend leuk onderzoek, 
en is het nu aan jullie om Lydia scherp te houden! Maryam, you were very quite 
when you first joined as our roommate. But soon you understood our chaotic 
room-order, and it has been great fun to hear you behind me, trying to stay quiet, 
but not being able to stop yourself from laughing at one of the jokes being made. 
Not long after that you became one of the instigators of fun and I want to thank 
you for adding joy to the room. Noortje, bedankt voor je humor en gezelligheid 
in onze kamer. En natuurlijk voor de mogelijkheden die je me bood om je in te 
maken met squash (al lukt dat helaas niet altijd even goed...) Hopelijk zullen we 
dit nog lang voortzetten! Zabi, in de korte tijd dat je bij de groep hoort heb ik 
je nog niet goed leren kennen, maar je vriendelijke lach en gezellige groet doen 
me altijd goed. Diederik, je bent de nieuwste aanwinst in de groep en meteen 
iemand om rekening mee te houden. Momenteel bezig met de eerste grote proef, 
en ik hoop dat het allemaal voorspoedig zal verlopen. Bedankt dat jij tijdens de 
NWO dagen de plaats innam van diegene die volgens Sander bij mij op de kamer 
zou zitten... J! 
Naast de gezellige samenwerking met de NMG-AIOs, heb ik natuurlijk veel mee-
gemaakt met alle andere AIOs van de vakgroep Humane Voeding. Bij deze wil ik 
hen alle bedanken voor de leuke en gezellig tijd die ik heb gehad bij de vakgroep. 
Daarnaast wil ik met name de mensen bedanken die samen met mij de PhD-reis 
naar Engeland en Ierland hebben georganiseerd: David, Renate, Pascalle, Ma-
rieke, Martinet en Gerda. We hebben niet alleen veel geleerd van deze organisa-
tie, maar ook enorm veel lol gehad. Ook alle mensen die mee waren op deze reis 
en de reis naar de Verenigde Staten, hartelijk dank voor alle lol en bus-quizen, en 
gezellige en leerzame discussies. 
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Natuurlijk zijn er nog vele anderen die mij op verschillende manieren geholpen 
hebben in de laatste vier jaar. Shohreh, you are the most helpful person I have 
ever known, and you were always there to lend a hand and help out when some-
thing had to be done, no matter how tired you were. Thanks a lot for everything! 
We will definitely eat some pizza again! Mechteld, allereerst is het natuurlijk 
helemaal geweldig dat je mijn paranimf wilde worden. Ik vind het echt fantas-
tisch dat je samen met mijn zus naast me wilt staan op dat podium. Je stond ook 
altijd klaar de laatste jaren, en was altijd in voor een geintje. En natuurlijk heb je, 
samen met Jenny, al die microarrays voor me gedraaid. Helaas heb je me ook 
zover gekregen dat ik de Nijmeegse vierdaagse ben gaan lopen, maar, mede door 
jou, en natuurlijk ook Menno’s, instelling en gastvrijheid, ben ik erdoorheen geko-
men. Bedankt voor al je hulp de laatste jaren, maar natuurlijk ook voor je gezel-
ligheid, humor en gulle lach. Jenny, naast alle microarrays die je verwerkt hebt, 
nam je hulp met labwerk mij niet alleen enorm veel werk uit handen, vooral het 
laatste half jaar, maar wist ik ook zeker dat het in goede handen was. Je bent altijd 
enorm precies en kwam vaak met goede opmerkingen (waar ik dan natuurlijk 
weer helemaal niet aan gedacht had). Bedankt voor al je hulp en natuurlijk je ge-
zelligheid. Karin, bedankt voor je herinneringen al de keren dat ik weer vergeten 
was dat het mijn beurt was om het lab schoon te houden (en dat kwam best vaak 
voor!) Mieke, altijd in voor een geintje, en natuurlijk voor een dansavond. Ik hoop 
je daar nog vaak aan te zullen treffen. Carolien, altijd een vriendelijke lach, zelfs 
als je ’s avonds laat nog aan het werk was en ik verbaasd mijn hoofd om de deur 
stak omdat ik dacht alleen in het gebouw te zijn. Els, dank voor de ontzettend 
gezellige lunchgesprekken en natuurlijk ook bedankt voor het overhalen van Bas 
om mee te doen aan een van mijn sadistische voedingsproeven. Ik hoop dat hij 
me niet te onaardig vind J! Jan, altijd een gezellig praatje als ik je tegenkwam in 
de gang of op weg van of naar het Biotechnion, en natuurlijk bedankt voor al die 
mooie foto’s die je door de jaren heen hebt gemaakt. Nicole, die goede oude Bra-
bantse mentaliteit heb ik extra leren waarderen door jouw geweldige gezellige 
kijk op het leven. Vooral tijdens ons ‘uitje’ in Arizona hebben we veel gelachen en 
ik dank je dan ook voor je goedlachse humeur. Jocelijn, ik herinner me nog goed 
hoe we voor het filmpje voor Renger zo enorm gelachen hebben. Bedankt voor je 
oprechte interesse in mijn werk. (Pappa) Bart, dank voor je flauwe, maar vaak 
enorm grappige opmerkingen, en ik wens je veel succes toe met de gezinsuitbrei-
ding. Philip, hartelijk dank voor de verwerking van de microarray data. Anneke, 
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maar weinig mensen beschikken over de vertelkunst die jij hebt laten horen en ik 
dank je dan ook hartelijk voor de vele lachbuien die je me bezorgd hebt. Mark, je 
was nooit te beroerd om even wat in Genomatix te gooien of ergens anders even 
snel naar te kijken. Hartelijk dank hiervoor, en ook voor het rechthangen van de 
schilderijen tijdens de NuGO week in Oslo J! Roelof, bedankt voor je kritische 
opmerkingen en je oprecht betrokken vragen bij een aantal van mijn projecten. 
Renger, bedankt voor je enorm positieve uitstraling, waardoor iedere vraag tij-
dens de donderdagochtend besprekingen zeer welkom was. 
Hanneke, we hebben niet veel samen gewerkt, maar je was altijd degene die 
klaar stond als ik weer eens iets niet kon vinden op het lab. Erik, bedankt voor je 
gulle lach en humor tijdens de vierdaagse. Ik zal nooit vergeten dat ik rechts van 
je moet staan als ik een geintje ten koste van jou maak J! Stephane, thanks for 
your humor and for the help during my latest contacts with your lab. Marleen, 
je hebt een apart gevoel voor humor wat ik erg kan waarderen, en een gewel-
dig relativerende kijk op het leven. Bedankt voor de leuke gesprekken die we op 
onze kamer gehad hebben. Jolanda, voor je op avontuur ging naar Spanje heb-
ben we veel lol beleefd op onze kamer, waar ik toen “de nieuwe” was. Je hebt me 
meteen thuis laten voelen en me wegwijs gemaakt in de groep. Bedankt daarvoor 
en voor je gezellige gesprekken. Betrand, you were one of the people who was 
often present in the nights that I worked late, and you give one of the most cheer-
ful greets I know. Caroline, I loved to make fun of your French accent, and you 
always cheered me up with another opportunity to do so. Thanks for returning 
the favor... Pierluigi and Elvira, thanks for your presence in the weekends in the 
last few weeks of all our contracts. It was nice to know I was not the only one 
working on impossible hours. 
Ook enkele Master studenten hebben me geholpen tijdens het onderzoek en 
graag wil ik Bianca, Ronak, Sonja, Antje en Neele dan ook enorm bedanken 
voor hun inzet. 
Naast alle genoemde mensen zijn er verschillende personen geweest die me bij 
mijn werk ondersteund hebben. Hiervan wil ik enkele met naam noemen, om-
dat ze een belangrijke bijdrage hebben geleverd tijdens mijn werk. Verschillende 
bloedpriksters hebben me geholpen tijdens de interventiestudies en met name 
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Lucy, Jantien, Marga, Diana en Isabelle wil ik bedanken voor hun inzet. Ook 
zonder diëtistes was ik niet ver gekomen in deze studies, en vooral Els wil ik 
bedanken voor haar inspanningen. Ook Tineke, Betty en Truus wil ik bedan-
ken, voor het uitvoeren van enkele belangrijke labbepalingen. Daarnaast zijn 
Dione, Lidwien, Marie en Gea me meer dan eens te hulp geschoten. Dank 
voor jullie ondersteuning! Een beetje schone kamer draagt natuurlijk bij aan 
een mooi proefschrift en Susan deed jaren haar best om mijn altijd chao-
tisch bedekte bureau schoon te krijgen. Daarnaast dank voor het lenen van je 
scooter. Nogmaals excuses voor het te laat en niet geheel intact terugbrengen 
hiervan... 
Graag wil ik Baukje de Roos bedanken voor het plaatsnemen in mijn promo-
tiecommissie en het afreizen naar Wageningen, maar ook voor de bijzonder 
leuke tijd die we in Australië gehad hebben. I would like to show my gratitude 
to professor Hannelore Daniel and professor Wim Saris for their willingness 
to participate in my committee and to travel to Wageningen. Tevens wil ik hier 
professor Huub Savelkoul bedanken, voor het plaatsnemen in de promotiecom-
missie, maar ook voor het bieden van de mogelijkheid om verder te gaan in het 
onderzoek. Ik heb enorm veel zin om me de komende drie jaar in te zetten voor 
dit nieuwe project! 
Zonder vrijwilligers kom je in het humane onderzoek niet ver, en ik wil dan ook 
mijn dank uitspreken aan alle deelnemers van de verschillende interventie-
studies. Ik wil graag Professor Gert Jan Hiddink en de Nederlandse Zuivel 
Organisatie bedanken voor de financiering van dit project en de goede discus-
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